


=> d 11
 L1 HAS NO ANSWERS
 L1 STR



REP G1=(0-7) C
 VPA 7-1/5 U
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GGCAT IS LOQ SAT AT 10
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 3
 NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

=> d his 14


(FILE 'CAPLUS' ENTERED AT 15:02:03 ON 16 SEP 2008)

FILE 'STNGUIDE' ENTERED AT 15:03:19 ON 16 SEP 2008

FILE 'REGISTRY' ENTERED AT 15:04:38 ON 16 SEP 2008

L4 7017 S L1 FUL

=> d 18
 L8 HAS NO ANSWERS
 L8 STR



REP G1=(0-7) C
 VPA 7-1/5 U
 NODE ATTRIBUTES:
 NSPEC IS R AT 10
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 3
 NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

=> d his 19

(FILE 'REGISTRY' ENTERED AT 15:06:13 ON 16 SEP 2008)
L9 1376 SEARCH L8 SSS SUB=L4 FUL

=> d his l10

(FILE 'REGISTRY' ENTERED AT 15:06:13 ON 16 SEP 2008)
L10 5641 S L4 NOT L9

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 60.77 250.70

FILE 'CAPLUS' ENTERED AT 15:10:20 ON 16 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Sep 2008 VOL 149 ISS 12
FILE LAST UPDATED: 15 Sep 2008 (20080915/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l10

L11 59 L10

=> s l11 and (muscul? or muscl?)

71623 MUSCUL?

372294 MUSCL?

L12 2 L11 AND (MUSCUL? OR MUSCL?)

=> d bib abs hitstr 1-2

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:590513 CAPLUS

DN 148:561932

TI Preparation of N-(pyridylpyrimidinylaminophenyl) amides as protein kinase inhibitors

IN Chianelli, Donatella; Li, Xiaolin; Liu, Xiaodong; Loren, Jon; Molteni, Valentina; Nabakka, Juliet; Revesz, Laszlo; Perez, Lawrence B.; Brooks, Clinton; Wrona, Wojciech; Manley, Paul W.; Breitenstein, Werner


PA Irm LLC, Bermuda; Novartis A.-G.

SO PCT Int. Appl., 109pp.


CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008058037	A1	20080515	WO 2007-US83543	20071102
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2006-864378P	P	20061103		
OS	MARPAT 148:561932				
GI					



I



II

AB The invention provides a novel class of compds. I [X, Y = a bond, NH; R¹ = (un)substituted cyclohexyl, pyridinyl, quinolinyl, isoquinolinyl and Ph; R², R³ = halo, alkyl, alkoxy, haloalkyl and haloalkoxy; R⁴ = (un)substituted heteroaryl], pharmaceutical compns. comprising I and methods of using I to beat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-Kit, PDGFR α and PDGFR β kinases. E.g., a multi-step synthesis of II.HCl, starting

from 2-amino-4-nitrotoluene and cyanamide, was given. Compds. I were tested against various kinases. For example, I have an IC50 in the range of 10 nM to 2 µM when tested in FGFR3 enzymic assay.


IT 1025714-57-1P 1025715-37-0P 1025715-38-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridylpyrimidinylaminophenyl amides as protein kinase inhibitors useful in treatment and prevention of disorders associated with abnormal kinase activity)


RN 1025714-57-1 CAPLUS

CN 5-Thiazolecarboxamide, 4-methyl-2-(1-methyl-4-piperidinyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1025715-37-0 CAPLUS

CN 5-Thiazolecarboxamide, N-[3-[[4-(5-methoxy-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-methyl-2-(4-piperidinyl)- (CA INDEX NAME)



RN 1025715-38-1 CAPLUS

CN 5-Thiazolecarboxamide, N-[3-[[4-(5-methoxy-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-methyl-2-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1291107 CAPLUS

DN 144:32869

TI cDNAs encoding human G protein-coupled receptor RUP43 associated with
metabolic disorders, atherosclerosis, heart disease, stroke, hypertension
and peripheral vascular disease and methods for drug screening

IN Qiu, Jun; Webb, Robert R.; Unett, David J.; Gatlin, Joel E.; Connolly,
Daniel T.

PA Arena Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 1/1 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005116653	A2	20051208	WO 2005-US12447	20050412
WO 2005116653	A3	20060518		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005248722	A1	20051208	AU 2005-248722	20050412
CA 2564139	A1	20051208	CA 2005-2564139	20050412
EP 1735622	A2	20061227	EP 2005-780020	20050412
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK			
CN 101027560	A	20070829	CN 2005-80018730	20050412
JP 2007532135	T	20071115	JP 2007-508478	20050412
IN 2006KN03236	A	20070608	IN 2006-KN3236	20061106
US 20070231263	A1	20071004	US 2006-604178	20061122
FRAI US 2004-561954P	P	20040413		
WO 2005-US12447	W	20050412		

US 2006-578257 A1 20061012

OS MARPAT 144:32869

AB The present invention relates to methods of identifying modulators of a human G protein-coupled receptor (GPCR) RUP43 or a modulator of blood glucose concentration. Agonists of the invention are useful as therapeutic agents

for lowering blood glucose concentration, for preventing or treating certain metabolic disorders, such as insulin resistance, impaired glucose tolerance, and diabetes, and for preventing or treating a complication of an elevated blood glucose concentration, such as atherosclerosis, heart


disease, stroke, hypertension and peripheral vascular disease.

IT 870476-98-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(cDNAs encoding human GPCR RUP43 associated with metabolic disorders, atherosclerosis, heart disease, stroke, hypertension and peripheral vascular disease and methods for drug screening)

RN 870476-98-5 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-(4,5,6,7-tetrahydro-2-methyl-2H-indazol-3-yl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

IT 870476-96-3P 870477-00-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cDNAs encoding human GPCR RUP43 associated with metabolic disorders, atherosclerosis, heart disease, stroke, hypertension and peripheral vascular disease and methods for drug screening)


RN 870476-96-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-(4,5,6,7-tetrahydro-2-methyl-2H-indazol-3-yl)- (CA INDEX NAME)



RN 870477-00-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-fluorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-(4,5,6,7-tetrahydro-2-methyl-2H-indazol-3-yl)- (CA INDEX NAME)



=> s l11 not l12
L13 57 L11 NOT L12

=> s l13 and py<=2002
22958911 PY<=2002
L14 9 L13 AND PY<=2002

=> d bib abs hitstr

L14 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:3696 CAPLUS
DN 140:59904
TI Preparation of triazole nucleoside analogs as antiviral agents
IN Hong, Zhi; Girardet, Jean-luc; Ramasamy, Kanda; Lau, Johnson
PA Ribapharm, Inc., USA
SO U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U.S. Ser. No. 594,410.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040002596	A1	20040101	US 2002-318476	20021213
	US 6815542	B2	20041109		
	US 6495677	B1	20021217	US 2000-594410	20000616 <--
	CN 1438891	A	20030827	CN 2001-807745	20010215
	CN 1817349	A	20060816	CN 2005-10131797	20010215
	DE 20121305	U1	20021024	DE 2001-20121305	20010315 <--
PRAI	US 2000-594410	A2	20000616		
	US 2000-182676P	P	20000215		
	US 2000-189672P	P	20000315		
	CN 2001-807745	A3	20010215		
	EP 2001-920509	A	20010315		
OS	MARPAT 140:59904				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Triazole nucleoside analogs I, wherein the sugar is either in the L- or D-configuration; Z is O, CH₂, or S; R is independently H, hydroxyl, protected hydroxyl or halogen; R₁-R₅, are independently selected from H, halogen, CN, CH₂OH, lower alkyl, vinyl, and acetylene radical; with the proviso that when R₂ is hydroxyl, then, R that is attached to the same carbon as that of R₂ is not halogen; when R₃ is hydroxyl, then, R that is


attached to the same carbon as that of R3 is not halogen; R6 is O-monoboranophosphate, O-diboranophosphate, O-triboranophosphate, O-monoboranophosphate, O-diboranophosphate, or O-triboranophosphate; R7 is selected from H, alkyl, CH₃COO-, CH₃COO-phenyl-CH₂-O-CO-, Ph, -(CH₂)_n-COOH, coumarinic acid, salicylic acid, dithiosuccinoyl, reductase mediated cleavable group, phosphonoformic acid, and phosphoramidate; R8 is selected from H, H⁺HCl, H⁺HBr, lower alkyl, Ph, CH₃COO-, CH₃COO-Phenyl-CH₂-O-CO-, carbamate, and phenyl; and wherein the nucleoside analog optionally forms a pharmacol. acceptable salt with an acid or a base. The novel compds., prodrugs, or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compns., and such compns. may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compds. may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 cytokine activity. Thus, triazole nucleoside analog II was prepared and tested as antiviral agent. The effect of title nucleosides on type 1 cytokine synthesis in SEB-activated human T-cells, is reported.

IT 637744-21-9P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of triazole nucleoside analogs as antiviral agents)

RN 637744-21-9 CAPLUS

CN Borate(1-), [2-[5-O-(dihydroxyphosphino-κP)-β-L-ribofuranosyl]-4-thiazolecarboxamidato(2-)]trihydro-, hydrogen, (T-4)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 2-9

L14 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:824002 CAPLUS

DN 138:395275

TI Simultaneous LC determination of tiazofurin, its acetyl and benzoyl esters and their active metabolite thiazole-4-carboxamide adenine dinucleotide in biological samples

AU Tasic, Jelena; Ristic, Slavica; Piperski, Vesna; Dacevic, Mirjana; Pejanovic, Vjera; Jokanovic, Milan; Mandic, Ljuba

CS ICN Galenika Institute, Center for Biomedical Research, Belgrade, 11000, Yugoslavia

SO Journal of Pharmaceutical and Biomedical Analysis (2002), 30(4), 993-999


CODEN: JPBADA; ISSN: 0731-7085

PB Elsevier Science B.V.

DT Journal

LA English
 IT 529505-79-1
 RL: ANT (Analyte); ANST (Analytical study)
 (simultaneous HPLC determination of tiazofurin and metabolites in biol.
 samples)
 RN 529505-79-1 CAPLUS
 CN 4-Thiazolecarboxamide, 2-(5-O-benzoyl-β-D-ribofuranosyl)- (CA INDEX
 NAME)


Absolute stereochemistry. Rotation (+).



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2002:742312 CAPLUS
 DN 138:153807
 TI Total synthesis and conformational studies of ceratospongamide, a
 bioactive cyclic heptapeptide from marine origin
 AU Yokokawa, Fumiaki; Sameshima, Hirofumi; In, Yasuko; Minoura, Katsuhiko;
 Ishida, Toshimasa; Shioiri, Takayuki
 CS Graduate School of Pharmaceutical Sciences, Nagoya City University,
 Mizuho-ku, Nagoya, 467-8603, Japan
 SO Tetrahedron (2002), 58(40), 8127-8143
 CODEN: TETRA; ISSN: 0040-4020
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 138:153807
 IT 358624-95-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (total synthesis, crystal structure, conformation and thermodyn.
 isomerization of cyclic heptapeptide ceratospongamide from marine
 origin by NMR, x-ray and mol. dynamic simulation)
 RN 358624-95-0 CAPLUS
 CN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-isoleucyl-L-allothroreonyl-L-
 phenylalanyl-2-(2S)-2-pyrrolidinyl-4-thiazolecarbonyl-L-phenylalanyl-,
 methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L14 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:732488 CAPLUS
DN 138:153344
TI Synthesis and antibacterial activity of 1 β -methyl-2-(5-substituted thiazolyl pyrrolidin-3-ylthio)carbapenem derivatives
AU Oh, Chang-Hyun; Cho, Han-Won; Baek, Daejin; Cho, Jung-Hyuck
CS Medicinal Chemistry Research Center, Korea Institute of Science and Technology, Seoul, 130-650, S. Korea
SO European Journal of Medicinal Chemistry (2002), 37(9), 743-754
CODEN: EJMCAS; ISSN: 0223-5234
PB Editions Scientifiques et Medicales Elsevier
DT Journal
LA English
OS CASREACT 138:153344
IT 496048-99-8P 496049-09-3P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, bactericidal activity, and structure-activity relationship of (thiazolyl pyrrolidinylthio)carbapenem derivs.)
RN 496048-99-8 CAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[[(3S,5S)-5-[4-(aminocarbonyl)-2-thiazolyl]methyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4R,5R,6S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496049-09-3 CAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[[(3S,5S)-5-[4-(aminocarbonyl)-2-thiazolyl]methyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4R,5R,6S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 496048-65-8P 496048-95-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation, bactericidal activity, and structure-activity relationship of
 (thiazolyl pyrrolidinylthio)carbapenem derivs.)
 RN 496048-65-8 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[4-(aminocarbonyl)-2-thiazolyl]-4-hydroxy-
 , (4-nitrophenyl)methyl ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 496048-95-4 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[4-(aminocarbonyl)-2-thiazolyl)methyl]-4-
 mercapto-, (4-nitrophenyl)methyl ester, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:535276 CAPLUS

DN 137:278997

TI Synthesis and antibacterial activity of 1 β -methyl-2-(5-substituted thiazolidinopyrrolidin-3-ylthio)carbapenems and related compounds

AU Oh, Chang-Hyun; Cho, Han-Won; Lee, In-Kyu; Gong, Jai-Yang; Choi, Jung-Hoon; Cho, Jung-Hyuck

CS Medicinal Chemistry Research Center, Korea Institute of Science and Technology, Seoul, 130-650, S. Korea

SO Archiv der Pharmazie (Weinheim, Germany) (2002), 335(4), 152-158

CODEN: ARPMA5; ISSN: 0365-6233

PB Wiley-VCH Verlag GmbH

DT Journal

LA English

OS CASREACT 137:278997

IT 466652-09-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and antibacterial activity of 1 β -methyl-2-(5-substituted thiazolidinopyrrolidin-3-ylthio)carbapenems from an aldehydic pyrrolidine)

RN 466652-09-5 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[[(3S,5S)-5-[(4R)-4-(aminocarbonyl)-2-thiazolidinyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4R,5S,6S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 466651-74-1P 466651-75-2P 466651-91-2P

466652-05-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and antibacterial activity of 1 β -methyl-2-(5-substituted thiazolidinopyrrolidin-3-ylthio)carbapenems from an aldehydic pyrrolidine)

RN 466651-74-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[(4R)-4-(aminocarbonyl)-2-thiazolidinyl]-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, (4-nitrophenyl)methyl ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 466651-75-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[(4R)-4-(aminocarbonyl)-2-thiazolidinyl]-4-[(methylsulfonyl)oxy]-, (4-nitrophenyl)methyl ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 466651-91-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[(4R)-4-(aminocarbonyl)-2-thiazolidinyl]-4-mercapto-, (4-nitrophenyl)methyl ester, (2S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 466652-05-1 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[(3S,5S)-5-[(4R)-4-(aminocarbonyl)-2-thiazolidinyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester, (4R,5S,6S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:466023 CAPLUS

DN 137:41715

TI Nucleotide derivatives and mycophenolic acid derivatives as antiviral agents for treatment of Flaviviridae infections and abnormal cellular proliferation, and preparation thereof

IN Stuyver, Lieven; Pankiewicz, Krzysztof W.; Patterson, Steven; Otto, Michael J.; Watanabe, Kyoichi A.

PA Pharmasset Ltd., USA

SO PCT Int. Appl., 165 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002048165	A2	20020620	WO 2001-US49231	20011217 <--
	WO 2002048165	A3	20030501		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2429352	A1	20020620	CA 2001-2429352	20011217 <--
	AU 2002032660	A2	20020624	AU 2002-32660	20011217 <--
	EP 1366055	A2	20031203	EP 2001-992193	20011217
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	CN 1527836	A	20040908	CN 2001-822665	20011217
	US 20040266723	A1	20041230	US 2001-23637	20011217
	JP 2005502580	T	20050127	JP 2002-549696	20011217
	BR 2001016221	A	20050913	BR 2001-16221	20011217
PRAI	US 2000-256066P	P	20001215		

WO 2001-US49231 W 20011217

OS MARPAT 137:41715

IT 437999-73-0 437999-73-0D, derivs. 437999-74-1
437999-74-1D, derivs.

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)


(antiviral agents for treatment of Flaviviridae infections and abnormal
cellular proliferation)

RN 437999-73-0 CAPLUS

CN Adenosine, 5'-ester with thiodiphosphoric acid ([(HO)2P(O)]2S),
P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—NH₂

RN 437999-73-0 CAPLUS

CN Adenosine, 5'-ester with thiodiphosphoric acid ([(HO)2P(O)]2S),
P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




—NH₂

RN 437999-74-1 CAPLUS

CN Adenosine, 5'-[hydrogen (fluorophosphonomethyl)phosphonate],
 P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—NH₂

RN 437999-74-1 CAPLUS

CN Adenosine, 5'-[hydrogen (fluorophosphonomethyl)phosphonate],
 P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



—NH₂


L14 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2002:307162 CAPLUS
 DN 137:109473
 TI Synthetic studies on ceratospongamides, cyclic heptapeptides containing
 thiazole and oxazoline units: total synthesis of cis,cis-ceratospongamide
 AU Kutsumura, Noriki; Sata, Noriko U.; Nishiyama, Shigeru
 CS Department of Chemistry, Faculty of Science and Technology, Keio
 University, Yokohama, 223-8522, Japan
 SO Bulletin of the Chemical Society of Japan (2002), 75(4), 847-850
 CODEN: BCSJA8; ISSN: 0009-2673
 PB Chemical Society of Japan
 DT Journal
 LA English
 OS CASREACT 137:109473
 IT 442682-29-3P 442682-30-6P 442682-31-7P
 442682-33-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of in the total synthesis of cis,cis-
 ceratospongamide)
 RN 442682-29-3 CAPLUS
 CN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-2-(2S)-2-
 pyrrolidinyl-4-thiazolecarbonyl-L-phenylalanyl-, methyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 442682-30-6 CAPLUS
 CN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-2-(2S)-2-
 pyrrolidinyl-4-thiazolecarbonyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 442682-31-7 CAPLUS

CN L-Allothreonine, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-2-(2S)-2-pyrrolidinyl-4-thiazolecarbonyl-L-phenylalanyl-L-prolyl-L-isoleucyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 442682-33-9 CAPLUS


CN L-Allothreonine, L-phenylalanyl-2-(2S)-2-pyrrolidinyl-4-thiazolecarbonyl-L-phenylalanyl-L-prolyl-L-isoleucyl-, methyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 442682-32-8

CMF C42 H55 N7 O8 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on SIN
AN 2001:747763 CAPLUS
DN 135:304037
TI Preparation of 2-hydroxymutillin carbamate derivatives as antibacterial
agents
IN Brooks, Gerald; Hunt, Eric
PA Smithkline Beecham Plc, UK
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001074788	A1	20011011	WO 2001-EP3594	20010329 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2405132	A1	20011011	CA 2001-2405132	20010329 <--
EP 1268443	A1	20030102	EP 2001-938069	20010329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				


BR	2001009809	A	20030121	BR	2001-9809	20010329
HU	2003000370	A2	20030628	HU	2003-370	20010329
HU	2003000370	A3	20050728			
JP	2003529593	T	20031007	JP	2001-572483	20010329
NZ	521536	A	20040528	NZ	2001-521536	20010329
AU	2001263827	B2	20040617	AU	2001-263827	20010329
IN	2002MN01325	A	20050304	IN	2002-MN1325	20020925
NO	2002004745	A	20021119	NO	2002-4745	20021002 <--
NO	324229	B1	20070910			
ZA	2002007912	A	20030514	ZA	2002-7912	20021002
KR	758441	B1	20070914	KR	2002-713202	20021002
MX	2002PA09816	A	20030327	MX	2002-PA9816	20021004
US	20030114674	A1	20030619	US	2002-240908	20021004
US	6972297	B2	20051206			
PRAI	GB 2000-8260	A	20000404			
	GB 2000-27182	A	20001104			
	WO 2001-EP3594	W	20010329			
OS	MARPAT 135:304037					
IT	365412-37-9P					

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-hydroxymutillin carbamate derivs. as antibacterial agents)

RN 365412-37-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[[(2S,3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-2,5-dihydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl]oxy]carbonyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 365412-52-8P 365412-68-6P 365412-69-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-hydroxymutillin carbamate derivs. as antibacterial agents)

RN 365412-52-8 CAPLUS

CN Carbamic acid, [[2-(4-piperidinyl)-4-thiazolyl]carbonyl]-, (2S,3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-2,5-dihydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365412-68-6 CAPLUS

CN Carbamic acid, [[2-[1-(2-amino-2-oxoethyl)-4-piperidinyl]-4-thiazolyl]carbonyl]-, (2S,3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-2,5-dihydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365412-69-7 CAPLUS


CN Carbamic acid, [[2-[1-(cyanomethyl)-4-piperidinyl]-4-thiazolyl]carbonyl]-, (2S,3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-2,5-dihydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 365412-09-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 2-hydroxymutilin carbamate derivs. as antibacterial agents)
 RN 365412-09-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[4-[[[(2S,3aS,4R,5S,6S,8R,9R,9aR,10R)-2-
 [(2,2-dichloroacetyl)oxy]-6-ethenyldecahydro-4,6,9,10-tetramethyl-1-oxo-5-
 [(2,2,2-trifluoroacetyl)oxy]-3a,9-propano-3aH-cyclopentacycloocten-8-
 yl]oxy]carbonyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester
 (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on SIN
 AN 2001:460589 CAPLUS
 DN 135:211278
 TI Total synthesis of cis,cis-ceratospongamide, a bioactive
 thiazole-containing cyclic peptide from marine origin
 AU Yokokawa, Fumiaki; Sameshima, Hirofumi; Shioiri, Takayuki
 CS Faculty of Pharmaceutical Sciences, Nagoya City University, Nagoya,
 467-8603, Japan
 SO Synlett (2001), (Spec. Issue), 986-988

CODEN: SYNLES; ISSN: 0936-5214

PB Georg Thieme Verlag

DT Journal

LA English

OS CASREACT 135:211278

IT 358624-95-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(total synthesis of cis,cis-ceratospongamide)

RN 358624-95-0 CAPLUS

CN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-isoleucyl-L-allothroonyl-L-phenylalanyl-2-(2S)-2-pyrrolidinyl-4-thiazolecarbonyl-L-phenylalanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:59:12 ON 16 SEP 2008)

FILE 'REGISTRY' ENTERED AT 14:59:26 ON 16 SEP 2008

L1 STRUC

L2 9 S L1

FILE 'CAPLUS' ENTERED AT 15:02:03 ON 16 SEP 2008

L3 2 S L2

FILE 'STNGUIDE' ENTERED AT 15:03:19 ON 16 SEP 2008

FILE 'REGISTRY' ENTERED AT 15:04:38 ON 16 SEP 2008

L4 7017 S L1 FUL

FILE 'CAPLUS' ENTERED AT 15:06:02 ON 16 SEP 2008

FILE 'REGISTRY' ENTERED AT 15:06:13 ON 16 SEP 2008

L5 386 S L4 AND AZETIDIN?

L6 0 S L4 AND AZETY?

L7 386 S L4 AND AZETI?

L8 STRUC

L9 1376 SEARCH L8 SSS SUB=L4 FUL
L10 5641 S L4 NOT L9

FILE 'CAPLUS' ENTERED AT 15:10:20 ON 16 SEP 2008

L11 59 S L10
L12 2 S L11 AND (MUSCUL? OR MUSCL?)
L13 57 S L11 NOT L12
L14 9 S L13 AND PY<=2002

=> s l13 not l14

L15 48 L13 NOT L14

=> d hitstr 48

L15 ANSWER 48 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

IT 662723-07-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(total synthesis of cis,cis-ceratospongamide, a cyclic peptide, via 4 +
3 fragment condensation, macrolactamization and subsequent
cyclodehydration)

RN 662723-07-1 CAPLUS

CN L-Allothreonine, N-[[2-(trimethylsilyl)ethoxy]carbonyl]-L-phenylalanyl-2-
(2S)-2-pyrrolidinyl-4-thiazolecarbonyl-L-phenylalanyl-L-prolyl-L-isoleucyl-
, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



=> d hitstr 47

L15 ANSWER 47 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

IT 615249-55-3P 615249-56-4P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
BIOL (Biological study); PREP (Preparation)

(preparation and anti-tumor activities of two tiazofurin analogs containing
modified sugar moieties)

RN 615249-55-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-(3-deoxy-3-fluoro-β-D-xylofuranosyl)- (CA
INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 615249-56-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[3-(acetylamino)-3-deoxy-β-D-xylofuranosyl]-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



=> d hitstr 46

L15 ANSWER 46 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN


IT 661489-49-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(synthesis and biol. evaluation of cyclosaligenyl-thiazofurin
monophosphate)

RN 661489-49-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-
β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 45

L15 ANSWER 45 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN


IT 676478-12-9P 676478-13-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(synthesis and antiviral and antitumor activity of (azido- and
aminodeoxy-β-D-ribofuranosyl)thiazolecarboxamide)

RN 676478-12-9 CAPLUS


CN 4-Thiazolecarboxamide, 2-(3-azido-3-deoxy- β -D-ribofuranosyl)- (CA
INDEX NAME)

Absolute stereochemistry.



RN 676478-13-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-(3-amino-3-deoxy- β -D-ribofuranosyl)- (CA
INDEX NAME)

Absolute stereochemistry.



=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

66.71

317.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.40

-2.40

FILE 'REGISTRY' ENTERED AT 15:15:06 ON 16 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 SEP 2008 HIGHEST RN 1049628-87-6

DICTIONARY FILE UPDATES: 15 SEP 2008 HIGHEST RN 1049628-87-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information

on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> d his

(FILE 'HOME' ENTERED AT 14:59:12 ON 16 SEP 2008)

FILE 'REGISTRY' ENTERED AT 14:59:26 ON 16 SEP 2008

L1 STRUC

L2 9 S L1

FILE 'CAPLUS' ENTERED AT 15:02:03 ON 16 SEP 2008

L3 2 S L2

FILE 'STNGUIDE' ENTERED AT 15:03:19 ON 16 SEP 2008

FILE 'REGISTRY' ENTERED AT 15:04:38 ON 16 SEP 2008

L4 7017 S L1 FUL

FILE 'CAPLUS' ENTERED AT 15:06:02 ON 16 SEP 2008

FILE 'REGISTRY' ENTERED AT 15:06:13 ON 16 SEP 2008

L5 386 S L4 AND AZETIDIN?

L6 0 S L4 AND AZETY?

L7 386 S L4 AND AZETI?

L8 STRUC

L9 1376 SEARCH L8 SSS SUB=L4 FUL

L10 5641 S L4 NOT L9

FILE 'CAPLUS' ENTERED AT 15:10:20 ON 16 SEP 2008

L11 59 S L10

L12 2 S L11 AND (MUSCUL? OR MUSCL?)

L13 57 S L11 NOT L12

L14 9 S L13 AND PY<=2002

L15 48 S L13 NOT L14

FILE 'REGISTRY' ENTERED AT 15:15:06 ON 16 SEP 2008

=> s l10 and (azetid? or pyrrolid? or piperid? or azepid?)

117821 AZETID?

886703 PYRROLID?

1490647 PIPERID?

0 AZEPID?

L16 4987 L10 AND (AZETID? OR PYRROLID? OR PIPERID? OR AZEPID?)


=> d scan

L16 4987 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN L-Cysteine, S-(phenylmethyl)-N-[[2-(4-piperidinyl)-4-thiazolyl]carbonyl]-, methyl ester

MF C20 H25 N3 O3 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l16 and piperidin?
 1484392 PIPERIDIN?
 L17 4875 L16 AND PIPERIDIN?

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	26.67	344.08
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.40

FILE 'CAPLUS' ENTERED AT 15:16:33 ON 16 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Sep 2008 VOL 149 ISS 12
 FILE LAST UPDATED: 15 Sep 2008 (20080915/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l17
 L18 27 L17

=> d bib 1-27

L18 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:916223 CAPLUS
 DN 149:200904
 TI Preparation of 4-thiazolylpiperidine derivs. as fungicides
 IN Pasteris, Robert James; Lahm, George Philip
 PA E. I. Du Pont de Nemours and Company, USA
 SO PCT Int. Appl., 133pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008091580	A2	20080731	WO 2008-US786	20080118
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2007-897792P	P	20070125		

L18 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:914474 CAPLUS
 DN 149:193346
 TI Preparation of carboxamide derivative fungicides for synergistic fungicidal mixtures
 IN Bruhn, John Anthony; Pasteris, Robert James
 PA E. I. Du Pont De Nemours and Company, USA
 SO PCT Int. Appl., 293pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008091594	A2	20080731	WO 2008-US813	20080118
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2007-897152P	P	20070124		
OS	MARPAT 149:193346				

L18 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:830080 CAPLUS
 DN 149:153071
 TI Preparation of substituted piperidinylthiazole derivatives and analogs for

in the treatment of diabetes and metabolic disorders
 IN Chen, Xin; Cheng, Peng; Clemens, L. Edward; Johnson, Jeffrey D.; Ma, Jingyuan; Murphy, Alison; Nashashibi, Imad; Rabbat, Christopher J.; Song, Jiangao; Wilson, Maria E.; Zhu, Yan; Zhao, Zuchun
 PA Metabolex Inc., USA
 SO PCT Int. Appl., 200pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008083238	A2	20080710	WO 2007-US88978	20071227
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2006-877903P	P	20061228		
	US 2007-964461	A	20071226		
OS	MARPAT 149:153071				

L18 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2008:636438 CAPLUS
 DN 149:9994
 TI Preparation of thiazolidine derivatives as antiviral agents
 IN Leivers, Martin Robert; Schmitz, Franz Ulrich; Griffith, Ronald Conrad; Roberts, Christopher Don; Dehghani Mohammad Abadi, Ali; Chan, Stephanie Anna; Rai, Roopa; Slobodov, Irina; Ton, Tony Loc
 PA Genelabs Technologies, Inc., USA
 SO PCT Int. Appl., 153pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008064218	A2	20080529	WO 2007-US85230	20071120
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 20080181866	A1	20080731	US 2007-943545	20071120
PRAI	US 2006-860545P	P	20061121		
	US 2007-943530P	P	20070612		
OS	MARPAT 149:9994				

L18 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:590513 CAPLUS
 DN 148:561932
 TI Preparation of N-(pyridylpyrimidinylaminophenyl) amides as protein kinase inhibitors
 IN Chianelli, Donatella; Li, Xiaolin; Liu, Xiaodong; Loren, Jon; Molteni, Valentina; Nabakka, Juliet; Revesz, Laszlo; Perez, Lawrence B.; Brooks, Clinton; Wrona, Wojciech; Manley, Paul W.; Breitenstein, Werner
 PA Irm LLC, Bermuda; Novartis A.-G.
 SO PCT Int. Appl., 109pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008058037	A1	20080515	WO 2007-US83543	20071102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2006-864378P	P	20061103		
OS MARPAT 148:561932				
RE.CNT 6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD			
	ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L18 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1238701 CAPLUS
 DN 147:502346
 TI Preparation of azolecarboxamide derivatives as trkA receptor inhibitors
 IN Sugawara, Keizo; Kawaguchi, Kenichi; Matsuzawa, Takaho; Seo, Ryushi; Harada, Hironori; Suga, Akira; Abe, Tomoaki; Azami, Hidenori; Matsumoto, Shunichiro; Shin, Takashi; Tanahashi, Masayuki; Watanabe, Toru
 PA Astellas Pharma Inc., Japan
 SO PCT Int. Appl., 234pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007123269	A1	20071101	WO 2007-JP59009	20070419
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW				

GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 PRAI JP 2006-115481 A 20060419

OS MARPAT 147:502346

RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1101576 CAPLUS

DN 147:479784

TI A novel class of potent NF- κ B signaling inhibitors

AU Leban, Johann; Baierl, Marcel; Mies, Jan; Trentinaglia, Viola; Rath, Sandra; Kronthaler, Kerstin; Wolf, Kristina; Gotschlich, Astrid; Seifert, Markus H. J.

CS 4SC AG, Martinsried, 82152, Germany

SO Bioorganic & Medicinal Chemistry Letters (2007), 17(21), 5858-5862

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Ltd.

DT Journal

LA English

OS CASREACT 147:479784

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1064465 CAPLUS

DN 147:385970

TI Novel heterocyclic NF- κ B inhibitors and their preparation,

pharmaceutical compositions and use in the treatment of diseases

IN Leban, Johann; Schmitt, Harald; Wolf, Kristina; Pegoraro, Stefano; Wuzik, Andreas; Krauss, Rolf

PA 4SC A.-G., Germany

SO PCT Int. Appl., 110pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007104557	A2	20070920	WO 2007-EP2265	20070314
	WO 2007104557	A3	20080522		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 20060247253	A1	20061102	US 2006-375259	20060315
	AU 2006278998	A1	20070215	AU 2006-278998	20060315
	CA 2617225	A1	20070215	CA 2006-2617225	20060315
	WO 2007016979	A2	20070215	WO 2006-EP2396	20060315
	WO 2007016979	A3	20070802		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,			

KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UB, US, UZ, VC,
 VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EF, OA

EP 1912982 A2 20080423 EP 2006-707574 20060315

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

CN 101233119 A 20080730 CN 2006-80027299 20080125

KR 2008031038 A 20080407 KR 2008-702431 20080129

IN 2008DN00806 A 20080704 IN 2008-DN806 20080129

NO 2008001056 A 20080228 NO 2008-1056 20080228

PRAI US 2006-375259 A 20060315

WO 2006-EP2396 A 20060315

US 2004-612794P P 20040927

US 2005-192009 A2 20050729

WO 2005-EP8261 A 20050729

OS MARPAT 147:385970

L18 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1064427 CAPLUS

DN 147:385969

TI Preparation of thiazoles as NF-kB inhibitors (proteasome inhibitors)

IN Leban, Johann; Vitt, Daniel

PA 4SC A.-G., Germany

SO PCT Int. Appl., 68pp.

CODEN: P1XXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007104558	A1	20070920	WO 2007-EP2266	20070314
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1834954 A1	20070919	EP 2006-5341	20060315	
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI EP 2006-5341 A	20060315			
US 2006-782486P P	20060315			
OS CASREACT 147:385969; MARPAT 147:385969				
RE.CNT 3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD			
	ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L18 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1052555 CAPLUS

DN 147:385967
 TI Preparation of thiazoles as NF-kB inhibitors (proteasome inhibitors)
 IN Leban, Johann; Vitt, Daniel
 PA 4SC AG, Germany
 SO Eur. Pat. Appl., 33pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1834954	A1	20070919	EP 2006-5341	20060315
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	US 20070219190	A1	20070920	US 2007-686263	20070314
	WO 2007104558	A1	20070920	WO 2007-EP2266	20070314
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2006-5341	A	20060315		
	US 2006-782486P	P	20060315		
OS	MARPAT 147:385967				

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1018570 CAPLUS
 DN 147:344079
 TI Preparation of thiazolylpiperidines for the treatment of diseases of liver and pancreas
 IN Otte, Marcus
 PA Oridis Biomed Forschungs- Und Entwicklungs GmbH, Austria
 SO Eur. Pat. Appl., 33pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1832586	A1	20070912	EP 2006-110952	20060310
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI	EP 2006-110952		20060310		
OS	CASREACT 147:344079; MARPAT 147:344079				
RE.CNT 3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L18 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:193428 CAPLUS
 DN 146:274350

TI Preparation of thiazolylpiperidines as histamine H3 receptor modulators.
 IN Nettekoven, Matthias Heinrich; Roche, Olivier
 PA F. Hoffmann-La Roche AG, Switz.
 SO PCT Int. Appl., 69pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007020213	A2	20070222	WO 2006-EP65167	20060809
	WO 2007020213	A3	20070412		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2006281435	A1	20070222	AU 2006-281435	20060809
	CA 2618568	A1	20070222	CA 2006-2618568	20060809
	EP 1945635	A2	20080723	EP 2006-792744	20060809
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	US 20070043083	A1	20070222	US 2006-502552	20060810
	MX 200802061	A	20080416	MX 2008-2061	20080212
	CN 101243078	A	20080813	CN 2006-80029914	20080215
	IN 2008DN01696	A	20080627	IN 2008-DN1696	20080227
	KR 2008035008	A	20080422	KR 2008-706254	20080314
PRAI	EP 2005-107586	A	20050818		
	WO 2006-EP65167	W	20060809		
OS	MARPAT 146:274350				

L18 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:117896 CAPLUS
 DN 146:206290

TI Preparation of fungicidal carboxamides

IN Bisaha, John Joseph; Kovacs, Patrick Ryan; Lett, Renee Marie; Long, Jeffrey Keith; Pasteris, Robert James; Finkelstein, Bruce Lawrence; Smith, Brenton Todd; Klyashchitsky, Boris Abramovich
 PA E. I. Du Pont De Nemours and Company, USA
 SO PCT Int. Appl., 267pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007014290	A2	20070201	WO 2006-US29175	20060726
	WO 2007014290	A3	20070607		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			

US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 AU 2006272551 A1 20070201 AU 2006-272551 20060726
 CA 2614288 A1 20070201 CA 2006-2614288 20060726
 EP 1948649 A2 20080730 EP 2006-800387 20060726
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, MK, RS
 IN 2007DN09576 A 20080627 IN 2007-DN9576 20071211
 MX 200801077 A 20080319 MX 2008-1077 20080123
 CN 101228156 A 20080723 CN 2006-80027100 20080124
 KR 2008031030 A 20080407 KR 2008-702106 20080125
 PRAI US 2005-702579P P 20050726
 WO 2006-US29175 W 20060726
 OS MARPAT 146:206290

L18 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1206440 CAPLUS

DN 145:489247

TI Preparation of 4-amino-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamides and
 related compounds as modulators of indoleamine 2,3-dioxygenase for
 inhibiting immunosuppression and treating various disorders

IN Combs, Andrew P.; Yue, Eddy W.

PA Incyte Corporation, USA

SO PCT Int. Appl., 154pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006122150	A1	20061116	WO 2006-US17983	20060509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006244068	A1	20061116	AU 2006-244068	20060509
CA 2606783	A1	20061116	CA 2006-2606783	20060509
US 20060258719	A1	20061116	US 2006-430441	20060509
EP 1879573	A1	20080123	EP 2006-759438	20060509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
IN 2007KN04130	A	20080328	IN 2007-KN4130	20071026
MX 200713977	A	20080205	MX 2007-13977	20071108
NO 2007005693	A	20080207	NO 2007-5693	20071108
KR 2008005954	A	20080115	KR 2007-726204	20071109
CN 101212967	A	20080702	CN 2006-80024326	20080103
PRAI US 2005-679507P	P	20050510		

WO 2006-US17983 W 20060509
 OS MARPAT 145:489247
 RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:1150357 CAPLUS
 DN 145:471514
 TI Novel 2-(piperidin-4-yl)thiazole derivatives as NF- κ B inhibitors and
 their preparation, pharmaceutical compositions, and use in the treatment
 of various diseases
 IN Leban, Johann; Schmitt, Harald; Wolf, Kristina; Pegoraro, Stefano; Wuzik,
 Andreas
 PA 4 Sc AG, Germany
 SO U.S. Pat. Appl. Publ., 52pp., Cont.-in-part of U.S. Ser. No. 192,009.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060247253	A1	20061102	US 2006-375259	20060315
	US 20060069102	A1	20060330	US 2005-192009	20050729
	WO 2007104557	A2	20070920	WO 2007-EP2265	20070314
	WO 2007104557	A3	20080522		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2004-612794P	P	20040927		
	US 2005-192009	A2	20050729		
	US 2006-375259	A	20060315		
	WO 2006-EP2396	A	20060315		
OS	MARPAT 145:471514				

L18 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:293220 CAPLUS
 DN 144:350663
 TI Thiazoles, oxazoles, imidazoles, and pyrroles as NF- κ B inhibitors,
 their preparation, pharmaceutical compositions, and use in therapy
 IN Leban, Johann; Schmitt, Harald; Wolf, Kristina; Pegoraro, Stefano; Wuzik,
 Andreas
 PA 4 Sc AG, Germany
 SO U.S. Pat. Appl. Publ., 37 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060069102	A1	20060330	US 2005-192009	20050729
	US 20060247253	A1	20061102	US 2006-375259	20060315
PRAI	US 2004-612794P	P	20040927		

OS US 2005-192009 A2 20050729
 MARPAT 144:350663

L18 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:1291107 CAPLUS

DN 144:32869

TI cDNAs encoding human G protein-coupled receptor RUP43 associated with
 metabolic disorders, atherosclerosis, heart disease, stroke, hypertension
 and peripheral vascular disease and methods for drug screening

IN Qiu, Jun; Webb, Robert R.; Unett, David J.; Gatlin, Joel E.; Connolly,
 Daniel T.

PA Arena Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 171 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005116653	A2	20051208	WO 2005-US12447	20050412
	WO 2005116653	A3	20060518		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005248722	A1	20051208	AU 2005-248722	20050412
	CA 2564139	A1	20051208	CA 2005-2564139	20050412
	EP 1735622	A2	20061227	EP 2005-780020	20050412
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK			
	CN 101027560	A	20070829	CN 2005-80018730	20050412
	JP 2007532135	T	20071115	JP 2007-508478	20050412
	IN 2006KN03236	A	20070608	IN 2006-KN3236	20061106
	US 20070231263	A1	20071004	US 2006-604178	20061122
PRAI	US 2004-561954P	P	20040413		
	WO 2005-US12447	W	20050412		
	US 2006-578257	A1	20061012		

OS MARPAT 144:32869

L18 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:1171558 CAPLUS

DN 143:440441

TI Preparation of piperidine derivatives as modulators of chemokine receptor
 CCR5

IN Faull, Alan; Tucker, Howard

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 122 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI	WO 2005101989	A2	20051103	WO 2005-SE574	20050420
	WO 2005101989	A3	20060427		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SE, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005235169	A1	20051103	AU 2005-235169	20050420
	CA 2562417	A1	20051103	CA 2005-2562417	20050420
	EP 1742934	A2	20070117	EP 2005-734934	20050420
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	CN 1972923	A	20070530	CN 2005-80020985	20050420
	BR 2005010126	A	20070626	BR 2005-10126	20050420
	JP 2007537335	T	20071122	JP 2007-509422	20050420
	MX 2006PA12045	A	20070125	MX 2006-PA12045	20061018
	KR 2007007345	A	20070115	KR 2006-721878	20061020
	US 20070167442	A1	20070719	US 2006-587330	20061020
	IN 2006DN06345	A	20070831	IN 2006-DN6345	20061030
	NO 2006005319	A	20070123	NO 2006-5319	20061120
FRAI	SE 2004-1057	A	20040423		
	SE 2005-57	A	20050110		
	WO 2005-SE574	W	20050420		
OS	CASREACT 143:440441; MARPAT 143:440441				
L18	ANSWER 19 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN				
AN	2005:1132909 CAPLUS				
DN	143:405902				
TI	Thiazolecarboxylic acid derivatives as inhibitors of histone deacetylase, their preparation, pharmaceutical compositions, and use in therapy				
IN	Anandan, Sampath K.; Xiao, Ziao-Yi; Patel, Dinesh V.; Ward, John S.				
PA	Miikana Therapeutics, USA				
SO	U.S. Pat. Appl. Publ., 53 pp.				
	CODEN: USXXCO				
DT	Patent				
LA	English				
FAN.CNT	1				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 20050234033	A1	20051020	US 2005-96550	20050401
	US 7345043	B2	20080318		
	US 20080139535	A1	20080612	US 2008-19356	20080124
FRAI	US 2004-559692P	P	20040401		
	US 2005-96550	A3	20050401		
OS	CASREACT 143:405902; MARPAT 143:405902				
L18	ANSWER 20 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN				
AN	2005:695268 CAPLUS				
DN	143:172873				
TI	Preparation of thiazolylimidazoles as microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (ApoB) inhibitors useful in the treatment of dyslipidemia and related diseases				

IN Guedat, Philippe; Chevreuil, Olivier; Convard, Thierry
 PA Merck Sante, Fr.
 SO Fr. Demande, 46 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2865733	A1	20050805	FR 2004-1046	20040204
	FR 2865733	B1	20071012		
	AU 2005210077	A1	20050818	AU 2005-210077	20050117
	CA 2555308	A1	20050818	CA 2005-2555308	20050117
	WO 2005074934	A1	20050818	WO 2005-EP388	20050117
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1711180	A1	20061018	EP 2005-700968	20050117
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
	JP 2007522138	T	20070809	JP 2006-551748	20050117
	US 20080214610	A1	20080904	US 2006-587975	20060803
PRAI	FR 2004-1046	A	20040204		
	WO 2005-EP388	W	20050117		

OS MARPAT 143:172873

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:395307 CAPLUS

DN 142:447208

TI Preparation of biaryl linked hydroxamates as histone deacetylase inhibitors

IN Stunkel, Walter; Wang, Haishan; Yin, Zheng

PA SBIO Pte Ltd, Singapore

SO PCT Int. Appl., 136 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040161	A1	20050506	WO 2004-SG354	20041026
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,			

SN, TD, TG
 EP 1682538 A1 20060726 EP 2004-775673 20041026
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 US 20070167499 A1 20070719 US 2007-577219 20070221
 PRAI US 2003-514012P P 20031027
 US 2003-532615P P 20031229
 WO 2004-SG354 W 20041026
 OS CASREACT 142:447208; MARPAT 142:447208
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:608 CAPLUS
 DN 142:93809
 TI Preparation of thiazolylpiperidines as microsomal triglyceride transfer
 protein (MTP) and/or apolipoprotein B (ApoB) inhibitors useful in the
 treatment of dyslipidemia and related diseases
 IN Guedat, Philippe; Collonges, Francois; Dumas, Herve; Ortholand, Jean Yves;
 Decerprit, Jacques; Barbanton, Jacques; Foster, Richard J.; Kane, Peter;
 Wendt, Bernd
 PA Merck Sante, Fr.
 SO Fr. Demande, 529 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2856685	A1	20041231	FR 2003-7670	20030625
	FR 2856685	B1	20050923		
	AU 2004253649	A1	20050113	AU 2004-253649	20040602
	CA 2531011	A1	20050113	CA 2004-2531011	20040602
	WO 2005003128	A1	20050113	WO 2004-EP5931	20040602
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1636218	A1	20060322	EP 2004-735742	20040602
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004011721	A	20060523	BR 2004-11721	20040602
	CN 1809560	A	20060726	CN 2004-80015739	20040602
	JP 2007506651	T	20070322	JP 2006-515818	20040602
	IN 2005KN02420	A	20070727	IN 2005-KN2420	20051129
	MX 2005PA13521	A	20060309	MX 2005-PA13521	20051213
	US 20070054939	A1	20070308	US 2005-561989	20051223
PRAI	FR 2003-7670	A	20030625		
	WO 2004-EP5931	W	20040602		
OS	MARPAT 142:93809				
RE.CNT 2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L18 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:1127897 CAPLUS
 DN 142:290596
 TI Evaluation and application of multiple scoring functions for a virtual screening experiment
 AU Xing, Li; Hodgkin, Edward; Liu, Qian; Sedlock, David
 CS Tripos, Inc., St. Louis, MO, 63144, USA
 SO Journal of Computer-Aided Molecular Design (2004), 18(5), 333-344
 CODEN: JCADEQ; ISSN: 0920-654X
 PB Kluwer Academic Publishers
 DT Journal
 LA English
 RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:566599 CAPLUS
 DN 141:123613
 TI Preparation of piperidinyl thiazole carboxamide derivatives for altering vascular tone
 IN Knox, Peter; Pappa, Helen; Lam, Winnie
 PA Metris Therapeutics Limited, UK
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004058751	A1	20040715	WO 2003-GB5654	20031224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003290335	A1	20040722	AU 2003-290335	20031224
AT 368662	T	20070815	AT 2003-789563	20031224
PRAI GB 2002-30162	A	20021224		
WO 2003-GB5654	W	20031224		
OS MARPAT 141:123613				

L18 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:566598 CAPLUS
 DN 141:123612
 TI Preparation of piperidinyl-thiazole carboxylic acid derivatives inhibitors of VEGF
 IN Knox, Peter; O'Sullivan, Michele; Lentfer, Heike
 PA Metris Therapeutics Limited, UK
 SO PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004058750	A1	20040715	WO 2003-GB5651	20031224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2511506 A1 20040715 CA 2003-2511506 20031224
 AU 2003294143 A1 20040722 AU 2003-294143 20031224
 EP 1581528 A1 20051005 EP 2003-789563 20031224
 EP 1581528 B1 20070801
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006513202 T 20060420 JP 2004-563361 20031224
 AT 368662 T 20070815 AT 2003-789563 20031224
 US 20060135501 A1 20060622 US 2005-540645 20051129
 PRAI GB 2002-30162 A 20021224
 WO 2003-GB5651 W 20031224
 OS MARPAT 141:123612

L18 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:412941 CAPLUS
 DN 140:423710
 TI Preparation of piperazinylalkylindoles as 5-HT1A and/or 5-HT1D agonists
 and as 5-HT reuptake inhibitors.
 IN Schiemann, Kai; Boettcher, Henning; Heinrich, Timo; Hoelzelmann, Guenter;
 Van Amsterdam, Christoph; Bartoszyk, Gerd; Leibrock, Joachim; Seyfried,
 Christoph
 PA Merck Patent G.m.b.H., Germany
 SO PCT Int. Appl., 59 pp.
 CODEN: P1XXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041815	A1	20040521	WO 2003-EP11132	20031008
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GR, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10252102 A1 20040527 DE 2002-10252102 20021108				
	AU 2003278057 A1 20040607 AU 2003-278057 20031008				
PRAI	DE 2002-10252102 A 20021108				
	WO 2003-EP11132 W 20031008				
OS	MARPAT 140:423710				
RE.CNT	4			THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD	
				ALL CITATIONS AVAILABLE IN THE RE FORMAT	

L18 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2001:747763 CAPLUS
 DN 135:304037
 TI Preparation of 2-hydroxymutillin carbamate derivatives as antibacterial


agents
 IN Brooks, Gerald; Hunt, Eric
 PA Smithkline Beecham Plc, UK
 SO PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001074788	A1	20011011	WO 2001-EP3594	20010329
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2405132	A1	20011011	CA 2001-2405132	20010329
	EP 1268443	A1	20030102	EP 2001-938069	20010329
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001009809	A	20030121	BR 2001-9809	20010329
	HU 2003000370	A2	20030628	HU 2003-370	20010329
	HU 2003000370	A3	20050728		
	JP 2003529593	T	20031007	JP 2001-572483	20010329
	NZ 521536	A	20040528	NZ 2001-521536	20010329
	AU 2001263827	B2	20040617	AU 2001-263827	20010329
	IN 2002MN01325	A	20050304	IN 2002-MN1325	20020925
	NO 2002004745	A	20021119	NO 2002-4745	20021002
	NO 324229	B1	20070910		
	ZA 2002007912	A	20030514	ZA 2002-7912	20021002
	KR 758441	B1	20070914	KR 2002-713202	20021002
	MX 2002PA09816	A	20030327	MX 2002-PA9816	20021004
	US 20030114674	A1	20030619	US 2002-240908	20021004
	US 6972297	B2	20051206		
FRAI	GB 2000-8260	A	20000404		
	GB 2000-27182	A	20001104		
	WO 2001-EP3594	W	20010329		
OS	MARPAT 135:304037				
RE.CNT 4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

=> d hitstr 27


L18 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2008 ACS on SIN
 IT 365412-37-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 2-hydroxymutinin carbamate derivs. as antibacterial agents)
 RN 365412-37-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[4-[[[(2S,3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-2,5-dihydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl]oxy]carbonyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 365412-52-8P 365412-68-6P 365412-69-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-hydroxymutilin carbamate derivs. as antibacterial agents)
 RN 365412-52-8 CAPLUS
 CN Carbamic acid, [[2-(4-piperidinyl)-4-thiazolyl]carbonyl]-, (2S,3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-2,5-dihydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365412-68-6 CAPLUS
 CN Carbamic acid, [[2-[1-(2-amino-2-oxoethyl)-4-piperidinyl]-4-thiazolyl]carbonyl]-, (2S,3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-2,5-dihydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365412-69-7 CAPLUS

CN Carbamic acid, [[2-[1-(cyanomethyl)-4-piperidinyl]-4-thiazolyl]carbonyl]-, (2S,3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-2,5-dihydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 365412-09-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-hydroxymutilin carbamate derivs. as antibacterial agents)

RN 365412-09-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[[(2S,3aS,4R,5S,6S,8R,9R,9aR,10R)-2-[(2,2-dichloroacetyl)oxy]-6-ethenyldecahydro-4,6,9,10-tetramethyl-1-oxo-5-[(2,2,2-trifluoroacetyl)oxy]-3a,9-propano-3aH-cyclopentacycloocten-8-yl]oxy]carbonyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 26

L18 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN


IT 692756-73-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of piperazinylalkylindoles as 5HT1A and/or 5HT1D agonists and as 5-HT reuptake inhibitors)

RN 692756-73-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[4-(5-cyano-1H-indol-3-yl)butyl]-4-piperidinyl]- (CA INDEX NAME)




IT 692756-90-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperazinylalkylindoles as 5HT1A and/or 5HT1D agonists and as 5-HT reuptake inhibitors)

RN 692756-90-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[4-(5-cyano-1H-indol-3-yl)butyl]-4-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

=> d hitstr 25

L18 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN


IT 721963-20-8P 721970-40-7P 721970-41-8P
 721970-42-9P 721970-43-0P 721970-44-1P
 721970-45-2P 721970-46-3P 721970-47-4P
 723242-54-4P 723242-55-5P 723242-56-6P
 723242-57-7P 723242-58-8P 723242-59-9P
 723242-60-2P 723242-61-3P 723242-62-4P
 723242-63-5P 723242-64-6P 723242-65-7P
 723242-66-8P 723242-67-9P 723242-68-0P
 723242-69-1P 723242-70-4P 723242-71-5P
 723242-72-6P 723242-73-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidinyl-thiazole carboxylic acid derivs. inhibitors of VEGF for the treatment of (VEGF)-mediated disorders)


RN 721963-20-8 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[2-(trifluoromethyl)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 721970-40-7 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[(4,7-dimethylpyrazolo[5,1-c][1,2,4]triazin-3-yl)carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 721970-41-8 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-(2-benzofuranylcarbonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 721970-42-9 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-(1-oxo-3-phenyl-2-propyn-1-yl)-4-piperidinyl]- (CA INDEX NAME)




RN 721970-43-0 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[(2-(2-propen-1-ylthio)-3-pyridinyl)carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 721970-44-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 721970-45-2 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[2-(3,4-dimethylphenoxy)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 721970-46-3 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[[[4-(dimethylamino)phenyl]amino]thioxomethyl]-4-piperidinyl]- (CA INDEX NAME)




RN 721970-47-4 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-([4-(2-pyridinyl)-1-piperazinyl]carbonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 723242-54-4 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 723242-55-5 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 723242-56-6 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[2-(4-fluorophenyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 723242-57-7 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[(2,2,3,3-tetramethylcyclopropyl)carbonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 723242-58-8 CAPLUS


CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[(4-methoxy-2-naphthalenyl)carbonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 723242-59-9 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[2-[2-(2-methoxyethoxy)ethoxy]acetyl]-4-piperidinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH₂


RN 723242-60-2 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-(2-chloro-6-fluorobenzoyl)-4-piperidinyl]- (CA INDEX NAME)




RN 723242-61-3 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-(2,3,4-trimethoxybenzoyl)-4-piperidinyl]- (CA INDEX NAME)




RN 723242-62-4 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-(4-methoxybenzoyl)-4-piperidinyl]- (CA INDEX NAME)




RN 723242-63-5 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[4-(1-methylethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 723242-64-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[[5-(aminocarbonyl)-2-methoxyphenyl]amino]carbonyl]-2-thiazolyl]-, 2-propyn-1-yl ester (CA INDEX NAME)




RN 723242-65-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-[4-[[[5-(aminocarbonyl)-2-methoxyphenyl]amino]carbonyl]-2-thiazolyl]-N-[2-(1-cyclohexen-1-yl)ethyl]- (CA INDEX NAME)



RN 723242-66-8 CAPLUS


CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[2-[4-(methylthio)phenyl]acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 723242-67-9 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[(1-phenyl-1H-pyrazol-4-yl)carbonyl]-4-piperidinyl]- (CA INDEX NAME)


PAGE 1-A






RN 723242-68-0 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-chlorophenyl]-2-[1-[2-(2-pyrimidinylthio)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 723242-69-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-chlorophenyl]-2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 723242-70-4 CAPLUS


CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-chlorophenyl]-2-[1-[2-(3-(dimethylamino)benzoyl)-4-piperidinyl]- (CA INDEX NAME)




RN 723242-71-5 CAPLUS
 CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-chlorophenyl]-2-[1-[3-(2-furanyl)-1-oxopropyl]-4-piperidinyl]- (CA INDEX NAME)



RN 723242-72-6 CAPLUS
 CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-chlorophenyl]-2-[1-[4-(3-buten-1-yloxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)



RN 723242-73-7 CAPLUS
 CN 4-Thiazolecarboxamide, N-[5-(2-amino-2-oxoethyl)-2-chlorophenyl]-2-[1-[3-(2-furanyl)-1-oxopropyl]-4-piperidinyl]- (CA INDEX NAME)



=>
 <-----User Break----->

=> d hitstr 24

L18 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 IT 721970-40-7P 721970-41-8P 721970-42-9P
 721970-43-0P 721970-44-1P 721970-45-2P

721970-46-3P 721970-47-4P 721970-59-8P


721970-60-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidinyl thiazole carboxamide derivs. for altering vascular tone)


RN 721970-40-7 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[(4,7-dimethylpyrazolo[5,1-c][1,2,4]triazin-3-yl)carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 721970-41-8 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-(2-benzofuranylcarbonyl)-4-piperidinyl]- (CA INDEX NAME)




RN 721970-42-9 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-(1-oxo-3-phenyl-2-propyn-1-yl)-4-piperidinyl]- (CA INDEX NAME)




RN 721970-43-0 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[[2-(2-propen-1-ylthio)-3-pyridinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 721970-44-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 721970-45-2 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[2-(3,4-dimethylphenoxy)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 721970-46-3 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[[[4-(dimethylamino)phenyl]amino]thioxomethyl]-4-piperidinyl]- (CA INDEX NAME)




RN 721970-47-4 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[[4-(2-pyridinyl)-1-piperazinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 721970-59-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[2-(1-cyclohexen-1-yl)ethyl]-4-[4-[(5,6-dimethyl-1H-benzimidazol-2-yl)amino]carbonyl]-2-thiazolyl]- (CA INDEX NAME)



RN 721970-60-1 CAPLUS


CN 4-Thiazolecarboxamide, N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-[1-(1-oxo-3-phenyl-2-propyn-1-yl)-4-piperidinyl]- (CA INDEX NAME)



=>
<-----User Break----->

=> d hitstr 23

L18 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
IT 847556-61-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(evaluation and application of multiple scoring functions for virtual
screening)
RN 847556-61-0 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[1-[(5-phenyl-1H-pyrazol-3-
yl)amino]carbonyl]-4-piperidinyl]-, 2-[(5-methyl-1H-pyrazol-3-
yl)carbonyl]hydrazide (CA INDEX NAME)




=> d hitstr 22

L18 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
IT 817182-26-6P, N-((Ciano)(4-fluorophenyl)methyl)-N-phenyl-2-[1-[(4'-
(trifluoromethyl)biphenyl-2-yl]carbonyl]piperidin-4-yl]thiazole-4-
carboxamide 817182-27-7P, N-(α-Cyanobenzyl)-N-ethyl-2-[1-
[(4'- (trifluoromethyl)biphenyl-2-yl]carbonyl]piperidin-4-yl]thiazole-4-
carboxamide 817182-30-2P, N-Methyl-N-(1-methyl-2-oxo-2-
phenylethyl)-2-[1-[(4'-trifluoromethyl)biphenyl-2-yl]carbonyl]piperidin-4-
yl]thiazole-4-carboxamide 817182-31-3P, N-Methyl-N-(1-methyl-2-
oxo-2(S)-phenylethyl)-2-[1-[(4'-trifluoromethyl)biphenyl-2-
yl]carbonyl]piperidin-4-yl]thiazole-4-carboxamide 817182-32-4P,
N-(7-Oxo-7H-thieno[3,2-b]pyran-6-yl)-2-[1-[(4'-trifluoromethyl)biphenyl-2-
yl]carbonyl]piperidin-4-yl]thiazole-4-carboxamide 817182-33-5P,
N-(2-Methyl-4-oxo-4H-chromen-3-yl)-2-[1-[(6-methyl-4'-
(trifluoromethoxy)biphenyl-2-yl]carbonyl]piperidin-4-yl]thiazole-4-
carboxamide 817182-34-6P, N-(α-Cyanobenzyl)-N-isopropyl-2-
[1-[(4'-trifluoromethyl)biphenyl-2-yl]carbonyl]piperidin-4-yl]thiazole-4-
carboxamide 817182-35-7P, N-[1-Cyano-1-(pyridin-4-yl)methyl]-N-
isopropyl-2-[1-[(4'-trifluoromethyl)biphenyl-2-yl]carbonyl]piperidin-4-
yl]thiazole-4-carboxamide 817182-36-8P 817182-37-9P
817182-38-0P 817182-39-1P 817182-41-5P
817182-45-9P 817182-47-1P 817182-49-3P
817182-51-7P 817182-55-1P 817182-58-4P
817182-61-9P 817182-70-0P 817182-72-2P
817182-74-4P 817182-78-8P 817182-79-9P
817182-80-2P 817182-82-4P 817182-83-5P
817182-84-6P 817182-85-7P 817182-88-0P
817182-90-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(apolipoprotein B secretion/microsomal triglyceride transfer protein
inhibitor; preparation of thiazolylpiperidines for treating dyslipidemia and

related disorders)


RN 817182-26-6 CAPLUS

CN 4-Thiazolecarboxamide, N-[cyano(4-fluorophenyl)methyl]-N-phenyl-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 817182-27-7 CAPLUS

CN 4-Thiazolecarboxamide, N-(cyanophenylmethyl)-N-ethyl-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 817182-30-2 CAPLUS


CN 4-Thiazolecarboxamide, N-methyl-N-[(1S)-1-methyl-2-oxo-2-phenylethyl]-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 817182-31-3 CAPLUS


CN 4-Thiazolecarboxamide, N-methyl-N-[(1S)-1-methyl-2-oxo-2-phenylethyl]-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 817182-32-4 CAPLUS

CN 4-Thiazolecarboxamide, N-(7-oxo-7H-thieno[3,2-b]pyran-6-yl)-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 817182-33-5 CAPLUS

CN 4-Thiazolecarboxamide, N-(2-methyl-4-oxo-4H-1-benzopyran-3-yl)-2-[1-[[6-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 817182-34-6 CAPLUS

CN 4-Thiazolecarboxamide, N-(cyanophenylmethyl)-N-(1-methylethyl)-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 817182-35-7 CAPLUS

CN 4-Thiazolecarboxamide, N-(cyano-4-pyridinylmethyl)-N-(1-methylethyl)-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 817182-36-8 CAPLUS


CN 4-Thiazolecarboxamide, N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl)-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 817182-37-9 CAPLUS


CN 4-Thiazolecarboxamide, N-methyl-N-[(1R)-1-methyl-2-oxo-2-phenylethyl]-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 817182-38-0 CAPLUS

CN 4-Thiazolecarboxamide, N-ethyl-N-[1-methyl-2-oxo-2-(3-pyridinyl)ethyl]-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 817182-39-1 CAPLUS

CN 4-Thiazolecarboxamide, N-ethyl-N-[1-methyl-2-oxo-2-(2-pyridinyl)ethyl]-2-[1-[[6-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 817182-41-5 CAPLUS

CN 4-Thiazolecarboxamide, N-(2-phenylethyl)-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 817182-45-9 CAPLUS

CN 4-Thiazolocarboxamide, N-(1-methyl-2-phenylethyl)-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidiny]- (CA INDEX NAME)



RN 817182-47-1 CAPLUS


CN 4-Thiazolocarboxamide, N-(2-hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidiny]- (CA INDEX NAME)



RN 817182-49-3 CAPLUS


CN 4-Thiazolocarboxamide, N-[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidiny]- (CA INDEX NAME)

Absolute stereochemistry.




RN 817182-51-7 CAPLUS

CN 4-Thiazolecarboxamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 817182-55-1 CAPLUS


CN 4-Thiazolecarboxamide, N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 817182-58-4 CAPLUS


CN L-Tyrosine, N-[[2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]-4-thiazolyl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 817182-61-9 CAPLUS

CN 4-Thiazolecarboxamide, N-(3-hydroxy-3-phenylpropyl)-N-methyl-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 817182-70-0 CAPLUS

CN 4-Thiazolecarboxamide, N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl)-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-3-piperidinyl]- (CA INDEX NAME)




RN 817182-72-2 CAPLUS

CN 4-Thiazolecarboxamide, N-ethyl-N-(2-hydroxy-1-methyl-2-phenylethyl)-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 817182-74-4 CAPLUS

CN 4-Thiazolecarboxamide, N-[2-(diethylamino)-2-oxo-1-phenylethyl]-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidiny]- (CA INDEX NAME)




RN 817182-78-8 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidiny]- (CA INDEX NAME)




RN 817182-79-9 CAPLUS


CN 4-Thiazolecarboxamide, N-(2-hydroxy-1-methyl-2-phenylethyl)-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidiny]- (CA INDEX NAME)




RN 817182-80-2 CAPLUS
 CN 4-Thiazolecarboxamide, N-(1,2-diphenylethyl)-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 817182-82-4 CAPLUS
 CN 4-Thiazolecarboxamide, N-(2,3-dihydro-2-oxo-1H-indol-3-yl)-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 817182-83-5 CAPLUS
 CN 4-Thiazolecarboxamide, N-[2-(4-fluorophenyl)-1,1-dimethylethyl]-2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)



RN 817182-84-6 CAPLUS
 CN 4-Thiazolecarboxamide, 2-[1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)

<-----User Break----->

=> d hitstr 21

L18 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 IT 1044043-33-5 1044043-40-4 1044043-71-1

1044043-72-2 1044043-75-5 1044043-76-6


1044043-77-7

RL: PRPH (Prophetic)

(Preparation of biaryl linked hydroxamates as histone deacetylase inhibitors)

RN 1044043-33-5 CAPLUS


CN 5-Thiazolecarboxamide, N-[[4-[5-[(hydroxyamino)carbonyl]-2-thienyl]phenyl]methyl]-4-phenyl-2-(4-piperidinyl)- (CA INDEX NAME)



RN 1044043-40-4 CAPLUS


CN 5-Thiazolecarboxamide, N-[[4-[4-[(1E)-3-(hydroxyamino)-3-oxo-1-propen-1-yl]phenyl]-2-thiazolyl]-4-methyl-2-(3-piperidinyl)- (CA INDEX NAME)

Double bond geometry as shown.




RN 1044043-71-1 CAPLUS


CN 5-Thiazolecarboxamide, N-[[3-[5-[(hydroxyamino)carbonyl]-2-thienyl]phenyl]methyl]-4-phenyl-2-(4-piperidinyl)- (CA INDEX NAME)



RN 1044043-72-2 CAPLUS
 CN 5-Thiazolecarboxamide, N-[[3-[5-[(hydroxyamino)carbonyl]-2-thienyl]phenyl]methyl]-4-methyl-2-(3-piperidinyl)- (CA INDEX NAME)




RN 1044043-75-5 CAPLUS
 CN 5-Thiazolecarboxamide, N-[[4-[5-[(hydroxyamino)carbonyl]-2-thienyl]phenyl]methyl]-4-methyl-2-(3-piperidinyl)- (CA INDEX NAME)




RN 1044043-76-6 CAPLUS

CN 5-Thiazolecarboxamide, N-[(4-{5-[(hydroxyamino)carbonyl]-3-thienyl}phenyl)methyl]-4-phenyl-2-(4-piperidinyl)- (CA INDEX NAME)




RN 1044043-77-7 CAPLUS


CN 5-Thiazolecarboxamide, N-[(4-{5-[(hydroxyamino)carbonyl]-3-phenyl}thienyl)phenyl)methyl]-4-methyl-2-(3-piperidinyl)- (CA INDEX NAME)



IT 851339-05-4P 851339-06-5P 851339-11-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of biaryl linked hydroxamates as histone deacetylase
 inhibitors)
 RN 851339-05-4 CAPLUS
 CN 5-Thiazolecarboxamide, N-[4-[5-[2-(hydroxyamino)-2-oxoethyl]-2-thienyl]-2-
 thiazolyl]-4-methyl-2-(3-piperidinyl)- (CA INDEX NAME)




RN 851339-06-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[5-[[[4-[5-[2-(hydroxyamino)-2-oxoethyl]-2-
 thienyl]-2-thiazolyl]amino]carbonyl]-4-methyl-2-thiazolyl]-,
 1,1-dimethylethyl ester (CA INDEX NAME)



RN 851339-11-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[[[4-[5-[2-(hydroxyamino)-2-oxoethyl]-2-

thienyl]-2-thiazolyl]amino]carbonyl]-4-phenyl-2-thiazolyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)




=>


<-----User Break----->

=> d hitstr 20

L18 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
IT 817181-89-8P, tert-Butyl 4-[4-[ethyl(1-methyl-2-oxo-2-phenylethyl)carbamoyl]thiazol-2-yl]piperidine-1-carboxylate
817181-94-5P, 4-[4-[Ethyl(1-methyl-2-oxo-2-phenylethyl)carbamoyl]thiazol-2-yl]piperidinium Chloride
861229-84-7P, 2-[2-[6-Methyl-4'-(trifluoromethoxy)biphenyl-2-yl]carbonyl]piperidin-4-yl]-N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl)thiazole-4-carboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thiazolylimidazoles as MTP and/or ApoB secretion inhibitors for treating dyslipidemia and related disorders)
RN 817181-89-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[[ethyl(1-methyl-2-oxo-2-phenylethyl)amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 817181-94-5 CAPLUS
CN 4-Thiazolecarboxamide, N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl)-2-(4-piperidinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 861229-84-7 CAPLUS

CN 4-Thiazolecarboxamide, N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl)-2-[2-[[6-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-2-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)



=> d hitstr 19

L18 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN


IT 867066-21-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of (hydroxyaminocarbonyl)thiazoles as inhibitors of histone deacetylase)

RN 867066-21-5 CAPLUS

CN 5-Thiazolecarboxamide, 2-[1-([1,1'-biphenyl]-4-ylsulfonyl)-4-piperidinyl]-N-hydroxy- (CA INDEX NAME)



=> d hitstr 18

L18 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

IT 868668-71-7P 868668-72-8P 868668-80-8P


868668-92-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine derivs. as modulators of chemokine receptor CCR5)


RN 868668-71-7 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[3-[1-(methylsulfonyl)-4-piperidinyl]-3-phenylpropyl]-4-piperidinyl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 868668-72-8 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[3-[1-(methylsulfonyl)-4-piperidinyl]-3-phenylpropyl]-4-piperidinyl]- (CA INDEX NAME)



RN 868668-80-8 CAPLUS

CN 4-Thiazolecarboxamide, N-(phenylmethyl)-2-[1-[(3S)-3-phenyl-3-[4-(phenylsulfonyl)-1-piperazinyl]propyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 868668-92-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[(3S)-3-phenyl-3-[4-(phenylsulfonyl)-1-piperazinyl]propyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 17

L18 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN


IT 870476-98-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(cDNAs encoding human GPCR RUP43 associated with metabolic disorders, atherosclerosis, heart disease, stroke, hypertension and peripheral vascular disease and methods for drug screening)

RN 870476-98-5 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-(4,5,6,7-tetrahydro-2-methyl-2H-indazol-3-yl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


IT 870476-96-3P 870477-00-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(cDNAs encoding human GPCR RUP43 associated with metabolic disorders, atherosclerosis, heart disease, stroke, hypertension and peripheral vascular disease and methods for drug screening)


RN 870476-96-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-(4,5,6,7-tetrahydro-2-methyl-2H-indazol-3-yl)- (CA INDEX NAME)



RN 870477-00-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-fluorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-(4,5,6,7-tetrahydro-2-methyl-2H-indazol-3-yl)- (CA INDEX NAME)



=> d hitstr 16

L18 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

IT 881196-06-1P, N-(1H-Benzimidazol-2-yl)-N'-[2-[1-(2-(trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazol-4-yl]carbonyl]guanidine
881196-22-1P, 2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide N-[5-(propan-1-ylsulfonyl)-1H-benzimidazol-2-yl]
881196-52-7P, 2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide N-(4-amino-6-oxo-1,6-dihydropyrimidin-2-yl)
881196-53-8P, 2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide N-(5-benzyl-4H-[1,2,4]triazol-3-yl)
881196-54-9P, 2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide N-(2-dimethylamino-6-oxo-1,6-dihydropyrimidin-4-yl)
881196-55-0P, 2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide N-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)
881196-56-1P, 2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide N-(4-dimethylamino-[1,3,5]triazin-2-yl)
881196-57-2P, 2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide N-(5-amino-1H-[1,2,4]triazol-3-yl)
881196-58-3P, N-Cyano-N'-[2-[1-(2-(trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazol-4-ylcarbonyl]guanidine 881196-59-4P
881196-60-7P, N-(1H-Benzimidazol-2-yl)-N'-[2-(1-(diphenylacetyl)piperidin-4-yl)-thiazol-4-ylcarbonyl]guanidine
881196-61-8P, N-(1H-Benzimidazol-2-yl)-N'-[2-(piperidin-4-yl)thiazol-4-ylcarbonyl]guanidine 881196-62-9P,
4-[4-[N'-(1H-Benzimidazol-2-yl)-guanidino]carbonyl]thiazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester 881196-66-3P,
2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide N-(1H-benzimidazol-2-yl) 881196-71-0P, 2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide N,N-bis-(4-chlorobenzyl) 881196-90-3P, 2-[1-(2-(4-Fluorophenyl)acetyl)piperidin-4-yl]-thiazole-4-carboxamide N-(5,6-dimethyl-1H-benzimidazol-2-yl) 881196-91-4P,
2-[1-[5-(4-Chlorophenyl)-2-trifluoromethylfuran-3-carbonyl]piperidin-4-yl]-thiazole-4-carboxamide N-(5,6-dimethyl-1H-benzimidazol-2-yl)
881196-92-5P, 2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide N-(5,6-dimethyl-1H-benzimidazol-2-yl)
881196-95-8P, 2-(Piperidin-4-yl)thiazole-4-carboxamide N-(5,6-dimethyl-1H-benzimidazol-2-yl) 881196-96-9P,
2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide N-[1-(1H-indol-2-yl)-ethyl]-N-methyl 881196-98-1P,
2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide N-methyl-N-(2-(morpholin-4-yl)-1-phenylethyl) 881196-99-2P,
2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide


N-benzyl-N-(2-hydroxyethyl) 881197-00-8P, 2-[1-(2-(Trifluoromethoxy)benzoyl)piperidin-4-yl]-thiazole-4-carboxamide
N-benzyl-N-phenethyl

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of thiazoles and other nitrogen heterocycles as NF-κB inhibitors)


RN 881196-06-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[(1H-benzimidazol-2-ylamino)iminomethyl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-22-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[6-(propylsulfonyl)-1H-benzimidazol-2-yl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-52-7 CAPLUS

CN 4-Thiazolecarboxamide, N-(4-amino-1,6-dihydro-6-oxo-2-pyrimidinyl)-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-53-8 CAPLUS

CN 4-Thiazolecarboxamide, N-[3-(phenylmethyl)-1H-1,2,4-triazol-5-yl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-54-9 CAPLUS

CN 4-Thiazolecarboxamide, N-[2-(dimethylamino)-1,6-dihydro-6-oxo-4-pyrimidinyl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-55-0 CAPLUS

CN 4-Thiazolecarboxamide, N-(1,6-dihydro-4-methyl-6-oxo-2-pyrimidinyl)-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-56-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[4-(dimethylamino)-1,3,5-triazin-2-yl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-57-2 CAPLUS

CN 4-Thiazolecarboxamide, N-(3-amino-1H-1,2,4-triazol-5-yl)-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-58-3 CAPLUS

CN 4-Thiazolecarboxamide, N-[(cyanoamino)iminomethyl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-59-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[[(1-acetyl-1H-benzimidazol-2-yl)amino](acetylimino)methyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 881196-60-7 CAPLUS

CN 4-Thiazolecarboxamide, N-[(1H-benzimidazol-2-ylamino)iminomethyl]-2-[1-(2,2-diphenylacetyl)-4-piperidinyl]- (CA INDEX NAME)




RN 881196-61-8 CAPLUS

CN 4-Thiazolecarboxamide, N-[(1H-benzimidazol-2-ylamino)iminomethyl]-2-[4-piperidinyl]- (CA INDEX NAME)




RN 881196-62-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[[(1H-benzimidazol-2-ylamino)iminomethyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 881196-66-3 CAPLUS

CN 4-Thiazolecarboxamide, N-1H-benzimidazol-2-yl-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-71-0 CAPLUS

CN 4-Thiazolecarboxamide, N,N-bis[(4-chlorophenyl)methyl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-90-3 CAPLUS

CN 4-Thiazolecarboxamide, N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-[1-[2-(4-fluorophenyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-91-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[5-(4-chlorophenyl)-2-(trifluoromethyl)-3-furanyl]carbonyl]-4-piperidiny]-N-(5,6-dimethyl-1H-benzimidazol-2-yl)- (CA INDEX NAME)




RN 881196-92-5 CAPLUS

CN 4-Thiazolecarboxamide, N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidiny]- (CA INDEX NAME)




RN 881196-95-8 CAPLUS

CN 4-Thiazolecarboxamide, N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-(4-piperidiny)- (CA INDEX NAME)




RN 881196-96-9 CAPLUS

CN 4-Thiazolecarboxamide, N-[1-(1H-indol-2-yl)ethyl]-N-methyl-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidiny]- (CA INDEX NAME)




RN 881196-98-1 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-N-[2-(4-morpholinyl)-1-phenylethyl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-99-2 CAPLUS

CN 4-Thiazolecarboxamide, N-(2-hydroxyethyl)-N-(phenylmethyl)-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)



RN 881197-00-8 CAPLUS

CN 4-Thiazolecarboxamide, N-(2-phenylethyl)-N-(phenylmethyl)-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)



=>

<-----User Break----->

=> d hitstr 15

L18 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

IT 881196-06-1P 881196-22-1P 881196-71-0P

881196-98-1P 881196-99-2P 881197-00-8P


913822-03-4P 913822-24-9P 913822-25-0P
 913822-35-2P 913822-36-3P 913822-37-4P
 913822-42-1P 913822-43-2P 913822-44-3P
 913822-45-4P 913822-46-5P 913822-47-6P
 913822-48-7P 913822-49-8P 913822-50-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of piperidinythiazole derivs. as NF- κ B
 inhibitors and their use in the treatment of various diseases)


RN 881196-06-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[(1H-benzimidazol-2-ylamino)iminomethyl]-2-[1-[2-
 (trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-22-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[6-(propylsulfonyl)-1H-benzimidazol-2-yl]-2-[1-[2-
 (trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-71-0 CAPLUS

CN 4-Thiazolecarboxamide, N,N-bis[(4-chlorophenyl)methyl]-2-[1-[2-
 (trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-98-1 CAPLUS

CN 4-Thiazolocarboxamide, N-methyl-N-[2-(4-morpholinyl)-1-phenylethyl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-99-2 CAPLUS

CN 4-Thiazolocarboxamide, N-(2-hydroxyethyl)-N-(phenylmethyl)-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881197-00-8 CAPLUS

CN 4-Thiazolocarboxamide, N-(2-phenylethyl)-N-(phenylmethyl)-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 913822-03-4 CAPLUS

CN 4-Thiazolocarboxamide, N-[2-(1H-indol-2-yl)ethyl]-N-methyl-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 913822-24-9 CAPLUS

CN 4-Thiazolocarboxamide, N-[(1H-benzimidazol-2-ylamino)iminomethyl]-2-[1-[4-(cyanophenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 913822-25-0 CAPLUS

CN 4-Thiazolecarboxamide, N-[(2-benzothiazolylamino)iminomethyl]-2-[1-[(4-cyanophenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 913822-35-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[(4-cyanophenyl)methyl]-4-piperidinyl]-N-[imino[(4-methyl-2-thiazolyl)amino)methyl]- (CA INDEX NAME)




RN 913822-36-3 CAPLUS

CN 4-Thiazolecarboxamide, N-[[5-chloro-1H-benzimidazol-2-yl)amino]iminomethyl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 913822-37-4 CAPLUS

CN 4-Thiazolecarboxamide, N-[[5,6-dichloro-1H-benzimidazol-2-yl)amino]iminomethyl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 913822-42-1 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-(1-furo[2,3-c]pyridin-4-yl-4-piperidiny)- (CA INDEX NAME)




RN 913822-43-2 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-piperidiny]- (CA INDEX NAME)



RN 913822-44-3 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-piperidiny]-N-(5-fluoro-2-benzothiazolyl)- (CA INDEX NAME)



RN 913822-45-4 CAPLUS


CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-[(4-

cyanophenyl)methyl]-4-piperidiny]- (CA INDEX NAME)




RN 913822-46-5 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[(1-thieno[3,2-d]pyrimidin-4-yl)-4-piperidiny]- (CA INDEX NAME)




RN 913822-47-6 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-[6-(trifluoromethyl)-4-pyrimidinyl]-4-piperidiny]- (CA INDEX NAME)




RN 913822-48-7 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[(4-cyanophenyl)methyl]-4-piperidiny]-N-(6-ethoxy-1H-benzimidazol-2-yl)- (CA INDEX NAME)



RN 913822-49-8 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-chloro-1H-benzimidazol-2-yl)-2-[1-[(4-cyanophenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 913822-50-1 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[(4-cyanophenyl)methyl]-4-piperidinyl]-N-(5,6-dichloro-1H-benzimidazol-2-yl)- (CA INDEX NAME)

<-----User Break----->

=> d hitstr 14


L18 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

IT 914474-03-6P, tert-Butyl 4-[4-[[[4-[(3-bromo-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl]amino]carbonyl]-1,3-thiazol-2-yl]piperidine-1-carboxylate 914474-06-9P, N-[4-[[[4-[(3-Bromo-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl]-2-(piperidin-4-yl)-1,3-thiazole-4-carboxamide monohydrochloride 914474-50-3P, N-[4-[[[4-[(3-Bromo-4-fluorophenyl)amino](hydroxyimino)methyl]-1,2,5-oxadiazol-3-yl]-2-(1-ethylpiperidin-4-yl)-1,3-thiazole-4-carboxamide mono(trifluoroacetate) RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 4-amino-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamides and related compds. as modulators of indoleamine 2,3-dioxygenase for inhibiting immunosuppression and treating various disorders)


RN 914474-03-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[[4-[(3-bromo-4-fluorophenyl)imino](hydroxyamino)methyl]-1,2,5-oxadiazol-3-yl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 914474-06-9 CAPLUS

4-Thiazolocarboxamide, N-[4-[[[3-bromo-4-fluorophenyl]imino](hydroxyamino)methyl]-1,2,5-oxadiazol-3-yl]-2-(4-piperidinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 914474-50-3 CAPLUS

4-Thiazolocarboxamide, N-[4-[[[3-bromo-4-fluorophenyl]imino](hydroxyamino)methyl]-1,2,5-oxadiazol-3-yl]-2-(1-ethyl-4-piperidinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 914474-49-0

CMF C20 H21 Br F N7 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



=>

<-----User Break----->

=> d hitstr 13

L18 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

IT 922512-32-1P 922512-33-2P 922512-34-3P
 922512-35-4P 922512-36-5P 922512-37-6P
 922512-38-7P 922512-39-8P 922512-40-1P
 922512-41-2P 922512-42-3P 922512-43-4P
 922512-44-5P 922512-45-6P 922512-46-7P
 922512-47-8P 922512-48-9P 922512-49-0P
 922512-50-3P 922512-51-4P 922512-52-5P
 922512-53-6P 922512-54-7P 922512-60-5P
 922512-61-6P 922512-63-8P 922512-64-9P
 922512-65-0P 922512-66-1P 922512-67-2P
 922512-68-3P 922512-69-4P 922512-70-7P
 922512-71-8P 922512-72-9P 922512-73-0P
 922512-74-1P 922512-75-2P 922512-76-3P
 922512-77-4P 922512-78-5P 922512-79-6P
 922512-86-5P 922512-87-6P 922512-88-7P
 922512-89-8P 922512-90-1P 922512-91-2P
 922512-92-3P 922512-93-4P 922512-94-5P
 922512-96-7P 922512-97-8P 922512-98-9P
 922512-99-0P 922513-00-6P 922513-01-7P
 922513-03-9P 922513-04-0P 922513-08-4P
 922513-09-5P 922513-10-8P 922513-11-9P
 922513-12-0P 922513-13-1P 922513-14-2P

922513-15-3P 922513-17-5P 922513-19-7P
 922513-20-0P 922513-22-2P 922513-24-4P
 922513-26-6P 922513-27-7P 922513-29-9P
 922513-31-3P 922513-33-5P 922513-34-6P
 922513-36-8P 922513-38-0P 922513-39-1P
 922513-40-4P 922513-41-5P 922513-42-6P
 922513-43-7P 922513-44-8P 922513-45-9P
 922513-46-0P 922513-47-1P 922513-48-2P
 922513-49-3P 922513-50-6P 922513-52-8P
 922513-53-9P 922513-55-1P 922513-56-2P
 922513-57-3P 922513-60-8P 922513-62-0P
 922513-64-2P 922513-65-3P 922513-66-4P
 922513-67-5P 922513-68-6P 922513-70-0P
 922513-71-1P 922513-72-2P 922513-74-4P
 922513-76-6P 922513-77-7P 922513-79-9P
 922513-81-3P 922513-82-4P 922513-83-5P
 922513-84-6P 922513-86-8P 922513-87-9P
 922513-89-1P 922513-90-4P 922513-91-5P
 922513-92-6P 922513-93-7P 922513-94-8P
 922513-95-9P 922513-96-0P 922513-97-1P
 922513-98-2P 922514-00-9P 922514-02-1P
 922514-03-2P 922514-05-4P 922514-06-5P
 922514-07-6P 922514-09-8P 922514-15-6P
 922514-20-3P 922514-21-4P 922514-22-5P
 922514-23-6P 922514-24-7P 922514-25-8P
 922514-26-9P 922514-27-0P 922514-28-1P
 922514-29-2P 922514-30-5P 922514-31-6P
 922514-32-7P 922514-33-8P 922514-34-9P
 922514-35-0P 922514-36-1P 922514-37-2P
 922514-38-3P 922514-39-4P 922514-40-7P
 922514-41-8P 922514-42-9P 922514-43-0P
 922514-44-1P 922514-45-2P 922514-46-3P
 922514-47-4P 922514-48-5P 922514-49-6P
 922514-50-9P 922514-51-0P 922514-52-1P
 922514-53-2P 922514-54-3P 922514-55-4P
 922514-56-5P 922514-57-6P 922514-58-7P
 922514-59-8P 922514-60-1P 922514-61-2P
 922514-62-3P 922514-65-6P 922514-66-7P
 922514-67-8P 922514-68-9P 922514-69-0P
 922514-70-3P 922514-71-4P 922514-72-5P
 922514-73-6P 922514-74-7P 922514-75-8P
 922514-76-9P 922514-80-5P 922514-82-7P
 922514-83-8P 922514-87-2P 922514-88-3P
 922514-89-4P 922514-90-7P 922514-91-8P
 922514-95-2P 922514-96-3P 922514-97-4P
 922514-98-5P 922514-99-6P 922515-00-2P
 922515-01-3P 922515-04-6P 922515-05-7P
 922515-07-9P 922515-09-1P 922515-10-4P
 922515-11-5P 922515-12-6P 922515-13-7P
 922515-14-8P 922515-15-9P 922515-16-0P
 922515-17-1P 922515-21-7P 922515-22-8P
 922515-23-9P 922515-24-0P 922515-25-1P
 922515-26-2P 922515-27-3P 922515-28-4P
 922515-29-5P 922515-30-8P 922515-34-2P
 922515-35-3P 922515-36-4P 922515-37-5P
 922515-38-6P 922515-39-7P 922515-40-0P


RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN
 (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of fungicidal carboxamides)

RN 922512-32-1 CAPLUS

CN 4-Thiazolocarboxamide, 2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-33-2 CAPLUS

CN 4-Thiazolocarboxamide, 2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-34-3 CAPLUS

CN 4-Thiazolocarboxamide, N-methyl-2-[1-(2-phenylacetyl)-4-piperidinyl]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-35-4 CAPLUS

CN 4-Thiazolocarboxamide, 2-[1-[2-(4-methoxyphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-36-5 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(3-methoxyphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-37-6 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,4-dichlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-38-7 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,6-dichlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 922512-39-8 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-bromophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

<-----User Break----->


Me



RN 922512-90-1 CAPLUS


CN 4-Thiazolecarboxamide, N-[(1R)-1-(4-chlorophenyl)ethyl]-2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 922512-91-2 CAPLUS


CN 4-Thiazolecarboxamide, N-[1-(3,5-dichloro-2-pyridinyl)ethyl]-N-methyl-2-[1-[2-(3-methylphenyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)



RN 922512-92-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-93-4 CAPLUS

CN 4-Thiazolecarboxamide, N-[(1R)-1-(4-bromophenyl)ethyl]-2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-94-5 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-
N-[(1R)-1-(4-fluorophenyl)ethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-96-7 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(3,5-dimethyl-1H-pyrazol-1-yl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 922512-97-8 CAPLUS


CN 4-Thiazolecarboxamide, N-methyl-N-[1-(3-pyridinyl)ethyl]-2-[1-[2-[3-(trifluoromethyl)phenyl]acetyl]-4-piperidinyl]- (CA INDEX NAME)



RN 922512-98-9 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-99-0 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-[(1R)-1-(3-methoxyphenyl)ethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-00-6 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-01-7 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(4-bromo-1H-pyrazol-1-yl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-03-9 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-2-[1-[2-(3-methyl-1H-pyrazol-1-yl)acetyl]-4-piperidinyl]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-04-0 CAPLUS


CN 4-Thiazolecarboxamide, N-methyl-2-[1-[2-(4-methyl-1H-pyrazol-1-yl)acetyl]-4-piperidinyl]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 922513-08-4 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-N-[1-(2-pyridinyl)ethyl]-2-[1-[2-[3-(trifluoromethyl)phenyl]acetyl]-4-piperidinyl]- (CA INDEX NAME)



RN 922513-09-5 CAPLUS


CN 4-Thiazolecarboxamide, N-methyl-N-[1-(4-pyridinyl)ethyl]-2-[1-[2-[3-(trifluoromethyl)phenyl]acetyl]-4-piperidinyl]- (CA INDEX NAME)



RN 922513-10-8 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dichlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-11-9 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-ethoxyphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-12-0 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(3-ethoxyphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-13-1 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(5-fluoro-2-methylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-14-2 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(5-bromo-2-methoxyphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 922513-15-3 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-(1-phenylbutyl)- (CA INDEX NAME)



RN 922513-17-5 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-N-[(1R)-1-phenylethyl]-2-[1-[2-(3-pyridinyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-19-7 CAPLUS


CN 4-Thiazolecarboxamide, N-methyl-N-[(1R)-1-phenylethyl]-2-[1-[2-(4-pyridinyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 922513-20-0 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-(1-phenylpentyl)- (CA INDEX NAME)



RN 922513-22-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-bromo-5-chlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-24-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-[2,5-bis(trifluoromethyl)phenyl]acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-26-6 CAPLUS


CN 4-Thiazolecarboxamide, N-methyl-N-[(1R)-1-phenylethyl]-2-[1-[2-(2-thienyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 922513-27-7 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[1-(2-thienyl)ethyl]- (CA INDEX NAME)



RN 922513-29-9 CAPLUS

CN Benzeneacetic acid, 2-[2-[4-[4-[[methyl[(1R)-1-phenylethyl]amino]carbonyl]-2-thiazolyl]-1-piperidinyl]-2-oxoethyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-31-3 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-2-[1-[2-(2-methyl-4-thiazolyl)acetyl]-4-piperidinyl]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-33-5 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethyl-4-thiazolyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-34-6 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-[3-(1,1-dimethylethyl)-5-isoxazolyl]acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 922513-36-8 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[1-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 922513-38-0 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[1-(3-pyridinyl)ethyl]- (CA INDEX NAME)




RN 922513-39-1 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-(2-methyl-1-phenylpropyl)- (CA INDEX NAME)



RN 922513-40-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-(3-methyl-1-phenylbutyl)- (CA INDEX NAME)




=>


<-----User Break----->

=> d hitstr 12


IT 926891-39-6P 926891-45-4P 926891-46-5P
 926891-47-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (claimed compound; preparation of thiazolylpiperidines as histamine H3
 receptor modulators)
 RN 926891-39-6 CAPLUS
 CN 4-Thiazolecarboxamide, N-(4-chlorophenyl)-2-[1-(1-methylethyl)-4-
 piperidinyl]- (CA INDEX NAME)




RN 926891-45-4 CAPLUS
 CN 4-Thiazolecarboxamide, 2-(1-cyclopentyl-4-piperidinyl)-N-phenyl- (CA
 INDEX NAME)



RN 926891-46-5 CAPLUS
 CN 4-Thiazolecarboxamide, N-(4-chlorophenyl)-2-(1-cyclopentyl-4-piperidinyl)-
 (CA INDEX NAME)



RN 926891-47-6 CAPLUS
 CN 4-Thiazolecarboxamide, 2-(1-cyclopentyl-4-piperidinyl)-N-(3-methoxyphenyl)-
 (CA INDEX NAME)



=> d hitstr 11


IT 948044-57-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazolylpiperidines for the treatment of diseases of liver and pancreas)

RN 948044-57-3 CAPLUS

CN Benzoic acid, 4-[[[2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]-4-thiazolyl]carbonyl]amino]-, 1-methylethyl ester (CA INDEX NAME)



IT 721970-44-1 948044-48-2 948044-49-3

948044-50-6 948044-51-7 948044-52-8

948044-53-9 948044-54-0 948044-55-1

948044-56-2 948044-59-5 948044-60-8

948044-61-9 948044-62-0 948044-63-1

948044-64-2 948044-65-3 948044-66-4

948044-67-5 948044-68-6 948044-69-7

948044-70-0 948044-71-1 948044-72-2

948044-74-4 948044-75-5 948044-76-6

948044-78-8 948044-79-9 948044-80-2

948044-81-3 948044-82-4 948044-84-6

948044-85-7 948044-86-8 948044-87-9

948044-88-0 948044-90-4 948044-91-5

948044-92-6 948044-93-7 948044-94-8

948044-95-9 948044-96-0 948044-98-2

948045-00-9 948045-01-0 948045-02-1

948045-03-2 948045-04-3 948045-05-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(preparation of thiazolylpiperidines for the treatment of diseases of liver and pancreas)


RN 721970-44-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(aminocarbonyl)-2-methoxyphenyl]-2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 948044-48-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 948044-49-3 CAPLUS

CN 4-Thiazolecarboxamide, N-(4-fluoro-3-nitrophenyl)-2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 948044-50-6 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]-N-6-quinolinyl- (CA INDEX NAME)




RN 948044-51-7 CAPLUS

CN 4-Thiazolecarboxamide, N-[(3,4-dimethoxyphenyl)methyl]-2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 948044-52-8 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]-N-(2-methyl-6-quinolinyl)- (CA INDEX NAME)




RN 948044-53-9 CAPLUS

CN 4-Thiazolecarboxamide, N-[2-(4-fluorophenyl)-1,1-dimethylethyl]-2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 948044-54-0 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]-N-(1-methyl-3-phenyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 948044-55-1 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]-N-[3-(5-oxazolyl)phenyl]- (CA INDEX NAME)




RN 948044-56-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]-N-2-thiazolyl- (CA INDEX NAME)




RN 948044-59-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[4-[[(6-methoxy-3-pyridinyl)amino]carbonyl]-2-thiazolyl]-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 948044-60-8 CAPLUS

CN 4-Thiazolecarboxamide, N-[3-(aminocarbonyl)-4-methyl-2-thienyl]-2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 948044-61-9 CAPLUS

CN 4-Thiazolecarboxamide, N-(3-fluoro-4-methylphenyl)-2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 948044-62-0 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[(2,4-dimethyl-5-thiazolyl)carbonyl]-4-piperidinyl]-N-[5-(2-thienyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 948044-63-1 CAPLUS
 CN 4-Thiazolecarboxamide, N-(4,5-dimethyl-2-thiazolyl)-2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidiny]- (CA INDEX NAME)




RN 948044-64-2 CAPLUS
 CN 4-Thiazolecarboxamide, N-[1-methyl-3-(2-thienyl)-1H-pyrazol-5-yl]-2-[1-[2-(trifluoromethyl)benzoyl]-4-piperidiny]- (CA INDEX NAME)



RN 948044-65-3 CAPLUS
 CN 4-Thiazolecarboxamide, 2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidiny]-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 948044-66-4 CAPLUS
 CN 4-Thiazolecarboxamide, N-(5-phenyl-1H-pyrazol-3-yl)-2-[1-(2,3,4-trimethoxybenzoyl)-4-piperidiny]- (CA INDEX NAME)




RN 948044-67-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[4-[[3-(cyclopropyl-1-methyl-1H-pyrazol-5-

yl)amino]carbonyl]-2-thiazolyl]-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 948044-68-6 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[(2,4-dimethyl-5-thiazolyl)carbonyl]-4-piperidinyl]-N-(1-methyl-3-phenyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 948044-69-7 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]-, 2-(2-methoxybenzoyl)hydrazide (CA INDEX NAME)




RN 948044-70-0 CAPLUS

CN 4-Thiazolecarboxamide, N-(3,4-difluorophenyl)-2-[1-[2-(1H-indol-3-yl)acetyl]-4-piperidinyl]- (CA INDEX NAME)




RN 948044-71-1 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(3,4-dimethylphenoxy)acetyl]-4-piperidinyl]-N-2-thiazolyl- (CA INDEX NAME)



RN 948044-72-2 CAPLUS
 CN 4-Thiazolecarboxamide, 2-[1-[(3-chloro-4-methylphenyl)sulfonyl]-4-piperidinyl]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



RN 948044-74-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[4-[(5-phenyl-1H-pyrazol-3-yl)amino]carbonyl]-2-thiazolyl-, 2-propyn-1-yl ester (CA INDEX NAME)



RN 948044-75-5 CAPLU
 <-----User Break----->


=> d hitstr 10

L18 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 IT 950587-81-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazoles as NF-KB inhibitors useful in treatment and prevention of diseases associated with abnormal and hyperproliferation of cells)

RN 950587-81-2 CAPLUS
 CN 4-Thiazolecarboxamide, N-(5-fluoro-2-benzothiazolyl)-2-(1-furo[2,3-c]pyridin-4-yl-4-piperidinyl)- (CA INDEX NAME)



=> d hitstr 9

L18 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN


IT 950587-81-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazoles as NF-KB inhibitors useful in treatment and prevention of diseases associated with abnormal and hyperproliferation of cells)

RN 950587-81-2 CAPLUS

CN 4-Thiazolecarboxamide, N-(5-fluoro-2-benzothiazolyl)-2-(1-furo[2,3-c]pyridin-4-yl-4-piperidinyl)- (CA INDEX NAME)



=> d hitstr 8

L18 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

IT 881196-06-1P 881196-22-1P 913822-24-9P


913822-25-0P 913822-35-2P 913822-36-3P
 913822-37-4P 913822-42-1P 913822-43-2P
 913822-44-3P 913822-45-4P 913822-46-5P
 913822-47-6P 913822-48-7P 913822-49-8P
 913822-50-1P 950674-89-2P 950674-90-5P
 950674-91-6P 950674-92-7P 950674-93-8P
 950674-94-9P 950674-95-0P 950674-96-1P
 950674-97-2P 950674-98-3P 950674-99-4P
 950675-00-0P 950675-01-1P 950675-02-2P
 950675-03-3P 950675-04-4P 950675-05-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heterocyclic NF-KB inhibitors useful in treatment and prevention of diseases associated with abnormal and hyperproliferation of cells)


RN 881196-06-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[(1H-benzimidazol-2-ylamino)iminomethyl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 881196-22-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[6-(propylsulfonyl)-1H-benzimidazol-2-yl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 913822-24-9 CAPLUS

CN 4-Thiazolecarboxamide, N-[(1H-benzimidazol-2-ylamino)iminomethyl]-2-[1-[(4-cyanophenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 913822-25-0 CAPLUS

CN 4-Thiazolecarboxamide, N-[(2-benzothiazolylamino)iminomethyl]-2-[1-[(4-cyanophenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 913822-35-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[(4-cyanophenyl)methyl]-4-piperidinyl]-N-[imino(4-methyl-2-thiazolyl)amino]methyl]- (CA INDEX NAME)




RN 913822-36-3 CAPLUS

CN 4-Thiazolecarboxamide, N-[[5-chloro-1H-benzimidazol-2-yl]amino]iminomethyl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 913822-37-4 CAPLUS

CN 4-Thiazolecarboxamide, N-[[5,6-dichloro-1H-benzimidazol-2-yl]amino]iminomethyl]-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)




RN 913822-42-1 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-(1-furo[2,3-c]pyridin-4-yl)-4-piperidinyl)- (CA INDEX NAME)




RN 913822-43-2 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-piperidinyl]- (CA INDEX NAME)




RN 913822-44-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-piperidinyl]-N-(5-fluoro-2-benzothiazolyl)- (CA INDEX NAME)




RN 913822-45-4 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-[(4-cyanophenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 913822-46-5 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidiny)- (CA INDEX NAME)




RN 913822-47-6 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-[6-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]- (CA INDEX NAME)




RN 913822-48-7 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[(4-cyanophenyl)methyl]-4-piperidinyl]-N-(6-ethoxy-1H-benzimidazol-2-yl)- (CA INDEX NAME)




RN 913822-49-8 CAPLUS
 CN 4-Thiazolecarboxamide, N-(6-chloro-1H-benzimidazol-2-yl)-2-[1-[(4-cyanophenyl)methyl]-4-piperidiny]- (CA INDEX NAME)




RN 913822-50-1 CAPLUS
 CN 4-Thiazolecarboxamide, 2-[1-[(4-cyanophenyl)methyl]-4-piperidiny]-N-(5,6-dichloro-1H-benzimidazol-2-yl)- (CA INDEX NAME)




RN 950674-89-2 CAPLUS
 CN 4-Thiazolecarboxamide, 2-[1-(2,6-dimethoxy-4-pyrimidinyl)-4-piperidiny]-N-[6-(3-thienylcarbonyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 950674-90-5 CAPLUS
 CN 4-Thiazolecarboxamide, 2-(1-thieno[3,2-d]pyrimidin-4-yl)-4-piperidiny]-N-[6-(3-thienylcarbonyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 950674-91-6 CAPLUS
 CN 4-Thiazolecarboxamide, 2-[1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-piperidinyl]-N-[6-(3-thienylcarbonyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 950674-92-7 CAPLUS
 CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-(2,6-dimethoxy-4-pyrimidinyl)-4-piperidinyl]- (CA INDEX NAME)




RN 950674-93-8 CAPLUS
 CN 4-Thiazolecarboxamide, N-(5-acetyl-2-benzothiazolyl)-2-(1-thieno[3,2-d]pyrimidin-4-yl)-4-piperidinyl- (CA INDEX NAME)




RN 950674-94-9 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(3-fluoro-4-methoxybenzoyl)-2-benzothiazolyl]-
2-(1-thieno[3,2-d]pyrimidin-4-yl)-4-piperidinyl- (CA INDEX NAME)



RN 950674-95-0 CAPLUS

CN 4-Thiazolecarboxamide, N-[5-(4-hydroxy-3-methoxybenzoyl)-2-benzothiazolyl]-
2-(1-thieno[3,2-d]pyrimidin-4-yl)-4-piperidinyl- (CA INDEX NAME)



RN 950674-96-1 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-(2-thienylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)

<-----User Break----->

=> d hitstr 7

L18 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

IT 881196-92-5P 913822-43-2P 913822-45-4P

913822-46-5P 913822-47-6P 950674-90-5P

950674-91-6P 950674-92-7P 950674-97-2P

950674-99-4P 950675-02-2P 950675-03-3P

950675-05-5P 954422-20-9P 954422-21-0P


954422-22-1P 954422-23-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(piperazines and benzimidazoles as NF- κ B signaling inhibitors)


RN 881196-92-5 CAPLUS

CN 4-Thiazolecarboxamide, N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-[1-(2-(trifluoromethoxy)benzoyl)-4-piperidinyl]- (CA INDEX NAME)




RN 913822-43-2 CAPLUS


CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-piperidinyl]- (CA INDEX NAME)




RN 913822-45-4 CAPLUS
 CN 4-Thiazolocarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-[(4-cyanophenyl)methyl]-4-piperidiny]- (CA INDEX NAME)



RN 913822-46-5 CAPLUS
 CN 4-Thiazolocarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl)-4-piperidiny]- (CA INDEX NAME)




RN 913822-47-6 CAPLUS
 CN 4-Thiazolocarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-[6-(trifluoromethyl)-4-pyrimidinyl]-4-piperidiny]- (CA INDEX NAME)




RN 950674-90-5 CAPLUS

CN 4-Thiazolecarboxamide, 2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)-N-[6-(3-thienylcarbonyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 950674-91-6 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-piperidinyl]-N-[6-(3-thienylcarbonyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 950674-92-7 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-(2,6-dimethoxy-4-pyrimidinyl)-4-piperidinyl]- (CA INDEX NAME)




RN 950674-97-2 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-(6,7-dimethoxy-4-quinazolinyl)-4-piperidinyl]- (CA INDEX NAME)




RN 950674-99-4 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-(9H-purin-6-yl)-4-piperidinyl]- (CA INDEX NAME)




RN 950675-02-2 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-(1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl-4-piperidiny1)- (CA INDEX NAME)




RN 950675-03-3 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-(2-methylpyrazolo[1,5-a]pyrimidin-7-yl)-4-piperidiny1]- (CA INDEX NAME)




RN 950675-05-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidine-2-carboxylic acid, 7-[4-[4-[(6-benzoyl-1H-benzimidazol-2-yl)amino]carbonyl]-2-thiazolyl]-1-piperidiny1]-, methyl ester (CA INDEX NAME)




RN 954422-20-9 CAPLUS

CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-(3-nitro-4-pyridinyl)-4-piperidinyl]- (CA INDEX NAME)




RN 954422-21-0 CAPLUS

CN 4-Thiazolecarboxamide, N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl)-4-piperidinyl- (CA INDEX NAME)



RN 954422-22-1 CAPLUS
 CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-[2-(trifluoromethoxy)benzoyl]-4-piperidinyl]- (CA INDEX NAME)



RN 954422-23-2 CAPLUS
 CN 4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-[(4,7-dimethylpyrazolo[5,1-c][1,2,4]triazin-3-yl)carbonyl]-4-piperidinyl]- (CA INDEX NAME)

<-----User Break----->

=> d hitstr 6

L18 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

IT 955390-04-2P 955390-05-3P 955390-06-4P
 955390-07-5P 955390-08-6P 955390-09-7P
 955390-44-0P 955390-47-3P 955390-48-4P
 955391-29-4P 955391-30-7P 955391-31-8P
 955391-38-5P 955391-40-9P 955391-41-0P
 955391-45-4P 955391-46-5P 955392-04-8P
 955392-17-3P 955392-21-9P 955392-24-2P
 955392-59-3P 955392-64-0P 955392-67-3P
 955394-86-2P 955394-87-3P 955394-88-4P
 955394-89-5P 955394-90-8P 955394-91-9P
 955394-92-0P 955394-93-1P 955394-94-2P
 955394-95-3P 955394-96-4P 955394-97-5P
 955394-98-6P 955394-99-7P 955395-00-3P
 955395-01-4P 955395-02-5P 955395-03-6P
 955395-04-7P 955395-05-8P 955395-06-9P
 955395-07-0P 955395-08-1P 955395-09-2P
 955395-10-5P 955395-11-6P 955395-12-7P
 955395-13-8P 955395-14-9P 955395-15-0P
 955395-16-1P 955395-17-2P 955395-18-3P
 955395-19-4P 955395-20-7P 955395-21-8P
 955395-22-9P 955395-23-0P 955395-24-1P
 955395-25-2P 955395-26-3P 955395-27-4P
 955395-28-5P 955395-29-6P 955395-30-9P
 955395-31-0P 955395-32-1P 955395-33-2P
 955395-34-3P 955395-35-4P 955395-36-5P
 955395-37-6P 955395-38-7P 955395-39-8P
 955395-40-1P 955395-41-2P 955395-42-3P
 955395-43-4P 955395-44-5P 955395-45-6P
 955395-46-7P 955395-47-8P 955395-48-9P
 955395-49-0P 955395-50-3P 955395-51-4P
 955395-52-5P 955395-53-6P 955395-54-7P
 955395-55-8P 955395-56-9P 955395-57-0P
 955395-58-1P 955395-59-2P 955395-60-5P
 955395-61-6P 955395-62-7P 955395-63-8P
 955395-64-9P 955395-65-0P 955395-66-1P

955395-69-4P 955395-71-8P 955395-74-1P


955395-76-3P 955395-79-6P 955395-80-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azolecarboxamide derivs. as trkA receptor inhibitors)


RN 955390-04-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[2-(4-methyl-1-piperazinyl)phenyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 955390-05-3 CAPLUS


CN 4-Thiazolecarboxamide, N-[2-(4-methyl-1-piperazinyl)phenyl]-2-(4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 955390-06-4 CAPLUS


CN 4-Thiazolecarboxamide, 2-(1-acetyl-4-piperidinyl)-N-[2-(4-methyl-1-piperazinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 955390-07-5 CAPLUS


CN 4-Thiazolecarboxamide, N-[2-(4-methyl-1-piperazinyl)phenyl]-2-(1-methyl-4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 955390-08-6 CAPLUS


CN 4-Thiazolecarboxamide, N-[2-(4-methyl-1-piperazinyl)phenyl]-2-[1-(methylsulfonyl)-4-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 955390-09-7 CAPLUS


CN 4-Thiazolecarboxamide, 2-(1-benzoyl-4-piperidinyl)-N-[2-(4-methyl-1-piperazinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 955390-44-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-[[2-(tetrahydro-2H-pyran-4-yl)-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955390-47-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-[[[2-(tetrahydro-2H-thiopyran-4-yl)-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955390-48-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-[[[2-(tetrahydro-3-furanyl)-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955391-29-4 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-(4-piperidiny)-4-thiazolyl]carbonyl]amino]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 955391-30-7 CAPLUS
CN 1-Piperazineacetamide, 4-[2-[[[2-(1-acetyl-4-piperidinyl)-4-thiazolyl]carbonyl]amino]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 955391-31-8 CAPLUS
CN 1-Piperidineacetic acid, 4-[4-[[[2-[4-(2-amino-2-oxoethyl)-1-piperazinyl]phenyl]amino]carbonyl]-2-thiazolyl]- (CA INDEX NAME)




RN 955391-38-5 CAPLUS
CN 1-Piperazineacetamide, 4-[2-[[[2-(1-acetyl-3-piperidinyl)-4-thiazolyl]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HC1

RN 955391-40-9 CAPLUS
 CN 1-Piperazineacetamide, 4-[2-[[[2-(3-piperidiny)-4-thiazolyl]carbonyl]amino]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HC1

RN 955391-41-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[4-[[[2-[4-(2-amino-2-oxoethyl)-1-piperazinyl]phenyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 955391-45-4 CAPLUS
 CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(2-amino-2-oxoethyl)-4-piperidiny]-4-thiazolyl]carbonyl]amino]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 955391-46-5 CAPLUS
CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(aminocarbonyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 955392-04-8 CAPLUS
CN 1-Piperazineacetamide, 4-[2-[[[2-(4-methyl-4-piperidinyl)-4-thiazolyl]carbonyl]amino]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 955392-17-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[[[2-[4-(2-amino-2-oxoethyl)-1-piperazinyl]phenyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

<-----User Break----->


CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(3-thienylcarbonyl)-4-piperidinyl]-4-

thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-10-5 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[2-(1-benzoyl-4-piperidinyl)-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-11-6 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[2-[1-(2-methylbenzoyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-12-7 CAPLUS


CN 1-Piperazineacetamide, 4-[2-[[2-[1-(3-methylbenzoyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 955395-13-8 CAPLUS
 CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(4-methylbenzoyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-14-9 CAPLUS
 CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(2-fluorobenzoyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-15-0 CAPLUS
 CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(3-fluorobenzoyl)-4-piperidinyl]-4-

thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-16-1 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(4-fluorobenzoyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-17-2 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(2-methoxybenzoyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-18-3 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(3-methoxybenzoyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-19-4 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(4-methoxybenzoyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-20-7 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-[2-(2-fluorophenyl)acetyl]-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-21-8 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-[2-(3-fluorophenyl)acetyl]-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-22-9 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-[2-(4-fluorophenyl)acetyl]-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-23-0 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(1-oxo-3-phenyl-2-propen-1-yl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-24-1 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-[1-oxo-3-(3-pyridinyl)propyl]-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-25-2 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(1-oxo-3-phenylpropyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-26-3 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(1-oxo-4-phenylbutyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-27-4 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(1-oxo-4-phenyl-3-buten-1-yl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-28-5 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(1-oxo-5-phenylpentyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-29-6 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(1,1'-biphenyl)-2-ylcarbonyl]-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-30-9 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-([1,1'-biphenyl]-3-ylcarbonyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-31-0 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-([1,1'-biphenyl]-4-ylcarbonyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-32-1 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-(1-propyl-4-piperidinyl)-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-33-2 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(cyclopropylmethyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-34-3 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(2-methylpropyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-35-4 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(2-methylpropyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-36-5 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(2-methoxyethyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-37-6 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(2-methoxyethyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-38-7 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[2-[1-[(tetrahydro-3-furanyl)methyl]-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-39-8 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[2-[1-(4-pyridinylmethyl)-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-40-1 CAPLUS


CN 1-Piperazineacetamide, 4-[2-[[2-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-41-2 CAPLUS
 CN 1-Piperazineacetamide, 4-[2-[[[2-[1-[(4-methylphenyl)methyl]-4-piperidiny]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 955395-42-3 CAPLUS
 CN 1-Piperazineacetamide, 4-[2-[[[2-[1-(3-phenylpropyl)-4-piperidiny]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-43-4 CAPLUS
 CN 1-Piperazineacetamide, 4-[2-[[[2-[1-[(2-methoxyphenyl)methyl]-4-piperidiny]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 955395-44-5 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-[(3-methoxyphenyl)methyl]-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 955395-45-6 CAPLUS

CN 1-Piperazineacetamide, 4-[2-[[[2-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]-4-thiazolyl]carbonyl]amino]phenyl]- (CA INDEX NAME)



=>

<-----User Break----->

=> dd hitstr 5

DD IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d hitstr 5

L18 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN


IT 1025714-57-1P 1025715-37-0P 1025715-38-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyridylpyrimidinylaminophenyl amides as protein kinase
inhibitors useful in treatment and prevention of disorders associated with
abnormal kinase activity)


RN 1025714-57-1 CAPLUS

CN 5-Thiazolecarboxamide, 4-methyl-2-(1-methyl-4-piperidinyl)-N-[4-methyl-3-
[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1025715-37-0 CAPLUS

CN 5-Thiazolecarboxamide, N-[3-[[4-(5-methoxy-3-pyridinyl)-2-
pyrimidinyl]amino]-4-methylphenyl]-4-methyl-2-(4-piperidinyl)- (CA INDEX
NAME)




RN 1025715-38-1 CAPLUS
 CN 5-Thiazolecarboxamide, N-[3-[[4-(5-methoxy-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-methyl-2-(1-methyl-4-piperidinyl)-(CA INDEX NAME)



=> d hitstr 4

L18 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 IT 1029799-31-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of thiazolidine derivs. as antiviral agents)
 RN 1029799-31-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[4R)-4-[[[4-(4-(cyclopropylamino)carbonyl]phenyl)-2-thiazolyl]amino]carbonyl]-3-[[phenylmethoxy)carbonyl]-2-thiazolidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



IT 1029798-57-9P 1029798-78-4P 1029799-66-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thiazolidine derivs. as antiviral agents)
 RN 1029798-57-9 CAPLUS
 CN 3-Thiazolidinecarboxylic acid, 4-[[[4-(4-(cyclopropylamino)carbonyl]phenyl

1]-2-thiazolyl]amino]carbonyl]-2-(3-piperidiny)-, phenylmethyl ester,
(4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1029798-78-4 CAPLUS

CN 3-Thiazolidinecarboxylic acid, 4-[[[4-[4-(cyclopropylamino)carbonyl]phenyl]-2-thiazolyl]amino]carbonyl]-2-(4-piperidiny)-, phenylmethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1029799-66-3 CAPLUS


CN 3-Thiazolidinecarboxylic acid, 2-(1-acetyl-3-piperidiny)-4-[[[4-[4-(cyclopropylamino)carbonyl]phenyl]-2-thiazolyl]amino]carbonyl]-, phenylmethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 1029800-27-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of thiazolidine derivs. as antiviral agents)
 RN 1029800-27-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(4R)-4-[[[4-[4-
 [(cyclopropylamino)carbonyl]phenyl]-2-thiazolyl]amino]carbonyl]-3-
 [(phenylmethoxy)carbonyl]-2-thiazolidinyl]-, 1,1-dimethylethyl ester (CA
 INDEX NAME)

Absolute stereochemistry.



=> d hitstr 3

L18 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 IT 1037793-74-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of substituted piperidinylthiazole derivs. and analogs for in
 the treatment of diabetes and metabolic disorders)
 RN 1037793-74-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[4-[[[4-(1H-tetrazol-1-
 yl)phenyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA
 INDEX NAME)



=> d hitstr 2


L18 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 IT 922515-97-7P 922515-98-8P 922516-01-6P
 922516-03-8P 922516-04-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate in preparation of carboxamide derivative fungicide)

RN 922515-97-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[methyl[(1R)-1-phenylpropyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 922515-98-8 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-N-[(1R)-1-phenylpropyl]-2-(4-piperidinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 922516-01-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[methyl[(1R)-1-phenylethyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 922516-03-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[methyl[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 922516-04-9 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-2-(4-piperidinyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 922512-32-1P 922512-33-2P 922512-34-3P
 922512-35-4P 922512-36-5P 922512-37-6P
 922512-38-7P 922512-39-8P 922512-40-1P
 922512-41-2P 922512-42-3P 922512-43-4P
 922512-44-5P 922512-45-6P 922512-46-7P
 922512-47-8P 922512-48-9P 922512-49-0P
 922512-50-3P 922512-51-4P 922512-52-5P
 922512-53-6P 922512-54-7P 922512-60-5P
 922512-61-6P 922512-63-8P 922512-64-9P
 922512-65-0P 922512-66-1P 922512-67-2P
 922512-68-3P 922512-69-4P 922512-70-7P
 922512-71-8P 922512-72-9P 922512-73-0P
 922512-74-1P 922512-75-2P 922512-76-3P
 922512-77-4P 922512-78-5P 922512-79-6P
 922512-86-5P 922512-87-6P 922512-88-7P
 922512-89-8P 922512-90-1P 922512-91-2P
 922512-92-3P 922512-93-4P 922512-94-5P
 922512-96-7P 922512-97-8P 922512-98-9P
 922512-99-0P 922513-00-6P 922513-01-7P
 922513-03-9P 922513-04-0P 922513-08-4P
 922513-09-5P 922513-10-8P 922513-11-9P
 922513-12-0P 922513-13-1P 922513-14-2P
 922513-15-3P 922513-17-5P 922513-19-7P

922513-20-0P 922513-22-2P 922513-24-4P
 922513-26-6P 922513-27-7P 922513-29-9P
 922513-31-3P 922513-33-5P 922513-34-6P
 922513-36-8P 922513-38-0P 922513-39-1P
 922513-40-4P 922513-41-5P 922513-42-6P
 922513-43-7P 922513-44-8P 922513-45-9P
 922513-46-0P 922513-47-1P 922513-48-2P
 922513-49-3P 922513-50-6P 922513-52-8P
 922513-53-9P 922513-55-1P 922513-56-2P
 922513-57-3P 922513-60-8P 922513-62-0P
 922513-64-2P 922513-65-3P 922513-66-4P
 922513-67-5P 922513-68-6P 922513-70-0P
 922513-71-1P 922513-72-2P 922513-74-4P
 922513-76-6P 922513-77-7P 922513-79-9P
 922513-81-3P 922513-82-4P 922513-83-5P
 922513-84-6P 922513-86-8P 922513-87-9P
 922513-89-1P 922513-90-4P 922513-91-5P
 922513-92-6P 922513-93-7P 922513-94-8P
 922513-95-9P 922513-96-0P 922513-97-1P
 922513-98-2P 922514-00-9P 922514-02-1P
 922514-03-2P 922514-05-4P 922514-06-5P
 922514-07-6P 922514-09-8P 922514-15-6P
 922514-20-3P 922514-21-4P 922514-22-5P
 922514-23-6P 922514-24-7P 922514-25-8P
 922514-26-9P 922514-27-0P 922514-28-1P
 922514-29-2P 922514-30-5P 922514-31-6P
 922514-32-7P 922514-33-8P 922514-34-9P
 922514-35-0P 922514-36-1P 922514-37-2P
 922514-38-3P 922514-39-4P 922514-40-7P
 922514-41-8P 922514-42-9P 922514-43-0P
 922514-44-1P 922514-45-2P 922514-46-3P
 922514-47-4P 922514-48-5P 922514-49-6P
 922514-50-9P 922514-51-0P 922514-53-2P
 922514-54-3P 922514-55-4P 922514-56-5P
 922514-57-6P 922514-58-7P 922514-59-8P
 922514-60-1P 922514-61-2P 922514-62-3P
 922514-65-6P 922514-66-7P 922514-68-9P
 922514-69-0P 922514-70-3P 922514-71-4P
 922514-72-5P 922514-73-6P 922514-74-7P
 922514-75-8P 922514-76-9P 922514-80-5P
 922514-82-7P 922514-83-8P 922514-87-2P
 922514-89-4P 922514-90-7P 922514-91-8P
 922514-96-3P 922514-97-4P 922514-98-5P
 922514-99-6P 922515-00-2P 922515-01-3P
 922515-04-6P 922515-05-7P 922515-07-9P
 922515-09-1P 922515-10-4P 922515-11-5P
 922515-12-6P 922515-13-7P 922515-14-8P
 922515-15-9P 922515-16-0P 922515-17-1P
 922515-21-7P 922515-22-8P 922515-24-0P
 922515-25-1P 922515-26-2P 922515-27-3P
 922515-28-4P 922515-29-5P 922515-30-8P
 922515-34-2P 922515-35-3P 922515-36-4P
 922515-37-5P 922515-38-6P 922515-39-7P
 922515-40-0P 922515-41-1P 922515-42-2P
 922515-43-3P 922515-44-4P 922515-45-5P
 922515-46-6P

RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation as fungicide for synergistic fungicidal mixts.)

RN 922512-32-1 CAPLUS

CN 4-Thiazolocarboxamide, 2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]-N-

methyl-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-33-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-34-3 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-2-[1-[2-(2-phenylacetyl)-4-piperidinyl]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-35-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(4-methoxyphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-36-5 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(3-methoxyphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 922512-37-6 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,4-dichlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.


<-----User Break----->



RN 922512-96-7 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(3,5-dimethyl-1H-pyrazol-1-yl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 922512-97-8 CAPLUS


CN 4-Thiazolecarboxamide, N-methyl-N-[1-(3-pyridinyl)ethyl]-2-[1-[2-(3-(trifluoromethyl)phenyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)



RN 922512-98-9 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-99-0 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-[(1R)-1-(3-methoxyphenyl)ethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-00-6 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidiny]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-01-7 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(4-bromo-1H-pyrazol-1-yl)acetyl]-4-piperidiny]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-03-9 CAPLUS

CN 4-Thiazolocarboxamide, N-methyl-2-[1-[2-(3-methyl-1H-pyrazol-1-yl)acetyl]-4-piperidiny]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-04-0 CAPLUS


CN 4-Thiazolocarboxamide, N-methyl-2-[1-[2-(4-methyl-1H-pyrazol-1-yl)acetyl]-4-piperidiny]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 922513-08-4 CAPLUS

CN 4-Thiazolocarboxamide, N-methyl-N-[1-(2-pyridinyl)ethyl]-2-[1-[2-[3-(trifluoromethyl)phenyl]acetyl]-4-piperidiny]- (CA INDEX NAME)



RN 922513-09-5 CAPLUS


CN 4-Thiazolocarboxamide, N-methyl-N-[1-(4-pyridinyl)ethyl]-2-[1-[2-[3-(trifluoromethyl)phenyl]acetyl]-4-piperidiny]- (CA INDEX NAME)



RN 922513-10-8 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dichlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-11-9 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-ethoxyphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-12-0 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(3-ethoxyphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-13-1 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(5-fluoro-2-methylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-14-2 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(5-bromo-2-methoxyphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 922513-15-3 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-(1-phenylbutyl)- (CA INDEX NAME)



RN 922513-17-5 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-N-[(1R)-1-phenylethyl]-2-[1-[2-(3-pyridinyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-19-7 CAPLUS


CN 4-Thiazolecarboxamide, N-methyl-N-[(1R)-1-phenylethyl]-2-[1-[2-(4-pyridinyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 922513-20-0 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-(1-phenylpentyl)- (CA INDEX NAME)



RN 922513-22-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-bromo-5-chlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-24-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-[2,5-bis(trifluoromethyl)phenyl]acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-26-6 CAPLUS


CN 4-Thiazolecarboxamide, N-methyl-N-[(1R)-1-phenylethyl]-2-[1-[2-(2-thienyl)acetyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 922513-27-7 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[1-(2-thienyl)ethyl]- (CA INDEX NAME)



RN 922513-29-9 CAPLUS

CN Benzeneacetic acid, 2-[2-[4-[4-[[methyl[(1R)-1-phenylethyl]amino]carbonyl]-2-thiazolyl]-1-piperidinyl]-2-oxoethyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-31-3 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-2-[1-[2-(2-methyl-4-thiazolyl)acetyl]-4-piperidinyl]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-33-5 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethyl-4-thiazolyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-34-6 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-[3-(1,1-dimethylethyl)-5-isoxazolyl]acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 922513-36-8 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[1-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 922513-38-0 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[1-(3-pyridinyl)ethyl]- (CA INDEX NAME)




RN 922513-39-1 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-(2-methyl-1-phenylpropyl)- (CA INDEX NAME)




RN 922513-40-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-(3-methyl-1-phenylbutyl)- (CA INDEX NAME)



RN 922513-41-5 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (CA INDEX NAME)



RN 922513-42-6 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 922513-43-7 CAPLUS


CN 4-Thiazolecarboxamide, N-(2,3-dihydro-1H-inden-1-yl)-2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 922513-44-8 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(2,4-dimethyl-1H-pyrrol-1-yl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 922513-45-9 CAPLUS

CN 4-Thiazolecarboxamide, N-(cyanophenylmethyl)-2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)




RN 922513-46-0 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-(1-phenyl-2-propen-1-yl)- (CA INDEX NAME)



RN 922513-47-1 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-
N-methyl-N-(1-phenyl-3-buten-1-yl)- (CA INDEX NAME)



RN 922513-48-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-
N-methyl-N-[(1R)-1-(1-naphthalenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-49-3 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-
N-methyl-N-[(1R)-1-(2-naphthalenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 922513-50-6 CAPLUS
 CN 4-Thiazolecarboxamide, 2-[1-[2-(3-bromophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 922513-52-8 CAPLUS
 CN 4-Thiazolecarboxamide, N-methyl-N-[(1R)-1-phenylpropyl]-2-[1-[2-[3-(trifluoromethyl)phenyl]acetyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 922513-53-9 CAPLUS
 CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-(2-methoxy-1-phenylethyl)-N-methyl- (CA INDEX NAME)



RN 922513-55-1 CAPLUS
 CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dichlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-56-2 CAPLUS

CN 4-Thiazolecarboxamide, N-[1-[(1R)-1-(3,5-dichloro-2-pyridinyl)ethyl]-2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 922513-57-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-[1-(2,5-dimethyl-3-thienyl)ethyl]-N-methyl- (CA INDEX NAME)

<-----User Break----->

=>

<-----User Break----->

=> d hitstr 2

L18 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

IT 922515-97-7P 922515-98-8P 922516-01-6P

922516-03-8P 922516-04-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate in preparation of carboxamide derivative fungicide)

RN 922515-97-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[methyl[(1R)-1-phenylpropyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 922515-98-8 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-N-[(1R)-1-phenylpropyl]-2-(4-piperidinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 922516-01-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[methyl[(1R)-1-phenylethyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 922516-03-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[methyl[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 922516-04-9 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-2-(4-piperidinyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 922512-32-1P 922512-33-2P 922512-34-3P
 922512-35-4P 922512-36-5P 922512-37-6P
 922512-38-7P 922512-39-8P 922512-40-1P
 922512-41-2P 922512-42-3P 922512-43-4P
 922512-44-5P 922512-45-6P 922512-46-7P
 922512-47-8P 922512-48-9P 922512-49-0P
 922512-50-3P 922512-51-4P 922512-52-5P
 922512-53-6P 922512-54-7P 922512-60-5P
 922512-61-6P 922512-63-8P 922512-64-9P
 922512-65-0P 922512-66-1P 922512-67-2P
 922512-68-3P 922512-69-4P 922512-70-7P
 922512-71-8P 922512-72-9P 922512-73-0P
 922512-74-1P 922512-75-2P 922512-76-3P
 922512-77-4P 922512-78-5P 922512-79-6P
 922512-86-5P 922512-87-6P 922512-88-7P
 922512-89-8P 922512-90-1P 922512-91-2P
 922512-92-3P 922512-93-4P 922512-94-5P
 922512-96-7P 922512-97-8P 922512-98-9P
 922512-99-0P 922513-00-6P 922513-01-7P
 922513-03-9P 922513-04-0P 922513-08-4P
 922513-09-5P 922513-10-8P 922513-11-9P
 922513-12-0P 922513-13-1P 922513-14-2P
 922513-15-3P 922513-17-5P 922513-19-7P

922513-20-0P 922513-22-2P 922513-24-4P
 922513-26-6P 922513-27-7P 922513-29-9P
 922513-31-3P 922513-33-5P 922513-34-6P
 922513-36-8P 922513-38-0P 922513-39-1P
 922513-40-4P 922513-41-5P 922513-42-6P
 922513-43-7P 922513-44-8P 922513-45-9P
 922513-46-0P 922513-47-1P 922513-48-2P
 922513-49-3P 922513-50-6P 922513-52-8P
 922513-53-9P 922513-55-1P 922513-56-2P
 922513-57-3P 922513-60-8P 922513-62-0P
 922513-64-2P 922513-65-3P 922513-66-4P
 922513-67-5P 922513-68-6P 922513-70-0P
 922513-71-1P 922513-72-2P 922513-74-4P
 922513-76-6P 922513-77-7P 922513-79-9P
 922513-81-3P 922513-82-4P 922513-83-5P
 922513-84-6P 922513-86-8P 922513-87-9P
 922513-89-1P 922513-90-4P 922513-91-5P
 922513-92-6P 922513-93-7P 922513-94-8P
 922513-95-9P 922513-96-0P 922513-97-1P
 922513-98-2P 922514-00-9P 922514-02-1P
 922514-03-2P 922514-05-4P 922514-06-5P
 922514-07-6P 922514-09-8P 922514-15-6P
 922514-20-3P 922514-21-4P 922514-22-5P
 922514-23-6P 922514-24-7P 922514-25-8P
 922514-26-9P 922514-27-0P 922514-28-1P
 922514-29-2P 922514-30-5P 922514-31-6P
 922514-32-7P 922514-33-8P 922514-34-9P
 922514-35-0P 922514-36-1P 922514-37-2P
 922514-38-3P 922514-39-4P 922514-40-7P
 922514-41-8P 922514-42-9P 922514-43-0P
 922514-44-1P 922514-45-2P 922514-46-3P
 922514-47-4P 922514-48-5P 922514-49-6P
 922514-50-9P 922514-51-0P 922514-53-2P
 922514-54-3P 922514-55-4P 922514-56-5P
 922514-57-6P 922514-58-7P 922514-59-8P
 922514-60-1P 922514-61-2P 922514-62-3P
 922514-65-6P 922514-66-7P 922514-68-9P
 922514-69-0P 922514-70-3P 922514-71-4P
 922514-72-5P 922514-73-6P 922514-74-7P
 922514-75-8P 922514-76-9P 922514-80-5P
 922514-82-7P 922514-83-8P 922514-87-2P
 922514-89-4P 922514-90-7P 922514-91-8P
 922514-96-3P 922514-97-4P 922514-98-5P
 922514-99-6P 922515-00-2P 922515-01-3P
 922515-04-6P 922515-05-7P 922515-07-9P
 922515-09-1P 922515-10-4P 922515-11-5P
 922515-12-6P 922515-13-7P 922515-14-8P
 922515-15-9P 922515-16-0P 922515-17-1P
 922515-21-7P 922515-22-8P 922515-24-0P
 922515-25-1P 922515-26-2P 922515-27-3P
 922515-28-4P 922515-29-5P 922515-30-8P
 922515-34-2P 922515-35-3P 922515-36-4P
 922515-37-5P 922515-38-6P 922515-39-7P
 922515-40-0P 922515-41-1P 922515-42-2P
 922515-43-3P 922515-44-4P 922515-45-5P
 922515-46-6P

RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation as fungicide for synergistic fungicidal mixts.)

RN 922512-32-1 CAPLUS

CN 4-Thiazolocarboxamide, 2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]-N-

methyl-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-33-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-chlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-34-3 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-2-[1-(2-phenylacetyl)-4-piperidinyl]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-35-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(4-methoxyphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-36-5 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(3-methoxyphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922512-37-6 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,4-dichlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 922512-38-7 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(2,6-dichlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

<-----User Break----->


e+^



RN 922513-49-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-(2-naphthalenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-50-6 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(3-bromophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-52-8 CAPLUS


CN 4-Thiazolecarboxamide, N-methyl-N-[(1R)-1-phenylpropyl]-2-[1-[2-[3-(trifluoromethyl)phenyl]acetyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 922513-53-9 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-(2-methoxy-1-phenylethyl)-N-methyl- (CA INDEX NAME)



RN 922513-55-1 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dichlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-56-2 CAPLUS


CN 4-Thiazolecarboxamide, N-[(1R)-1-(3,5-dichloro-2-pyridinyl)ethyl]-2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 922513-57-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-[1-(2,5-dimethyl-3-thienyl)ethyl]-N-methyl- (CA INDEX NAME)



RN 922513-60-8 CAPLUS


CN 4-Thiazolecarboxamide, N-[1-(2,5-dimethyl-3-furanyl)ethyl]-2-[1-[2-(2,5-dimethylphenyl)acetyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 922513-62-0 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-[2-chloro-5-(trifluoromethyl)phenyl]acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-64-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-[1-[2-(2-methoxyphenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-65-3 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-2-[1-[2-(3-methylphenyl)acetyl]-4-piperidinyl]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-66-4 CAPLUS

CN 4-Thiazolecarboxamide, N-methyl-2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 922513-67-5 CAPLUS


CN 4-Thiazolecarboxamide, 2-[1-[2-(3,5-dimethyl-1H-pyrazol-1-yl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 922513-68-6 CAPLUS
 CN 4-Thiazolecarboxamide, 2-[1-[2-(3-ethylphenyl)acetyl]-4-piperidiny]-N-methyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



=>


<-----User Break----->

=> d hitstr 1

L18 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
 IT 1041437-06-2P, Ethyl 4-[4-[[methyl(1,2,3,4-tetrahydro-1-naphthalenyl)amino]carbonyl]-2-thiazolyl]- α -[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]- β -oxo-1-piperidinepropanoate 1041437-18-6P
 RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-thiazolylpiperidine derivs. as fungicides)
 RN 1041437-06-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

IT 922514-49-6P, N-Methyl-2-[1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)thiazole-4-carboxamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 4-thiazolylpiperidine derivs. as fungicides)
 RN 922514-49-6 CAPLUS
 CN 4-Thiazolecarboxamide, N-methyl-2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-
 (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=>
 <-----User Break----->